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Cellular detoxification allows for the maintenance of cellular
homeostasis and prevention of abnormal cell growth by clearing harmful
xenobiotics and endobiotics. After oxygenation by phase I enzymes, phase II
enzymes such as glucuronosyltransferases and glutathione-s-transferases
conjugate a small molecule to the compound, marking it for subsequent
export. Many up-stream enzymes are also essential to cellular detoxification
by supplying the small compounds for conjugation. These up-stream enzymes
include UDP-glucose dehydrogenase, which synthesizes UDP-glucuronate,
and glutamate cysteine ligase, which catalyzes the first and rate-limiting step
in the synthesis of glutathione.
UDP-glucose dehydrogenase (UGDH) is an important enzyme in human
development and in the progression of many types of human epithelial
cancers. Recently, mutations in UGDH were identified that are associated
with congenital heart defects and cause a shift from a hexameric to a dimeric
state. These clinical mutants, along with two engineered dimer mutants were
used to examine differences in UGDH function resulting from loss of

hexameric structure. The dimer mutants exhibited near wild-type activity in
vitro, and significant differences in UDP-glucuronate levels were not observed
in HEK 293 cells. Despite this, the phenotype of development defects
associated with the UGDH clinical mutants is at least partially explained by a
reduction in protein stability.
Glutamate cysteine ligase (GCL) deficiency is a rare autosomal recessive
trait that compromises production of glutathione, a critical redox buffer and
enzymatic cofactor. Glutamate cysteine ligase is a heterodimer comprised of a
catalytic (GCLC) and a regulatory subunit (GCLM). Four clinical missense
mutations have been identified within GCLC: Arg127Cys, Pro158Leu,
His370Leu, and Pro414Leu. Embryonic fibroblasts from GCLC null mice were
transiently transfected with wild-type or mutant GCLC and cellular
glutathione levels were determined to be significantly lower in the mutants
relative to wild-type. In an S. cerevisiae model system, mutant GCLC alone
could not complement a glutathione-deficient strain and required the
concurrent addition of GCLM to restore growth. Kinetic characterizations of
the recombinant GCLC mutants indicated that the Arg127Cys, His370Leu, and
Pro414Leu mutants have compromised enzymatic activity that can largely be
rescued by the addition of GCLM, while the Pro158Leu mutant has kinetic
constants comparable to wild-type GCLC.
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Chapter 1
Introduction

2
1.1 Cellular detoxification pathways
Cellular detoxification pathways are essential to the maintenance of
cellular homeostasis and prevention of disease or progression of abnormal cell
growth. Small hydrophobic molecules diffuse freely across the plasma
membrane, allowing the entry of potentially harmful levels of xenobiotics or
endogenous compounds into the cell. Fortunately, cellular detoxification is
both efficient and broadly specific, allowing many different classes of
compounds to be effectively cleared from the cell in a 3-step process [1, 2].
First, phase I enzymes (primarily members of the cytochrome 450 family of
enzymes) oxygenate a compound, making it an appropriate substrate for
phase II enzymes. These enzymes, which include glucuronosyltransferases
and glutathione-s-transferases, conjugate a small molecule, such as
glucuronate or glutathione, to the compound. These conjugated molecules
mark the compound for subsequent export through multi-drug resistance
transporters [1, 2].
Besides phase I and phase II enzymes, a multitude of up-stream
enzymes participate in cellular detoxification by regulating the availability of
small molecules for conjugation to xenobiotics. Thus, UDP-glucose
dehydrogenase converts the common metabolite UDP-glucose into UDPglucuronate, which may then be used as a substrate by UDPglucuronosyltransferases (UGTs) or in glycosylation reactions in the lumen of
the ER [3]. Besides participating in clearance of xenobiotics, UGTs also
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glucuronidate endogenous compounds such as bilirubin and steroid hormones
allowing them to be exported from the cell [4].
Similarly, glutathione has a variety of important cellular fates after
sequential synthesis by glutamate cysteine ligase and glutathione synthetase.
Glutathione’s role as a redox regulator is well recognized [5, 6]. However,
glutathione is also used extensively by glutathione-S-transferases to tag
compounds for export and metabolize the by-products of oxidative stress [7].
The role of glutathione in cellular detoxification, like that of UDPglucuronate, is especially critical in the liver, where the rate of detoxification
is particularly high and a disproportionate amount of phase I, phase II, and
upstream enzymes are synthesized [4].
Because of the critical roles of these two enzymes in supplying
metabolites necessary for the detoxification of endobiotics and xenobiotics
and their other cellular roles in metabolism and redox homeostasis, UDPglucose dehydrogenase and glutamate cysteine ligase are ideal candidates for
structural studies to reveal the basis of in vivo and in vitro enzyme function.
1.2 Roles of UDP-glucuronate
UDP-glucuronate is an important cellular metabolite utilized as a
precursor in glycosaminoglycan synthesis, protein glycosylation, and cellular
detoxification [8,10, 13]. UDP-glucuronate is synthesized from UDP-glucose
by the enzyme UDP-glucose dehydrogenase via two successive oxidations to
convert the 6’ hydroxyl to a carboxylate. UDP-glucuronate has a variety of
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cellular fates, many of which involve further conversion at the ER or Golgi
lumen [9].
UDP-glucuronate is incorporated into glycosaminoglycans in a variety
of ways. The enzyme UDP-xylose synthase or UDP-glucuronate
decarboxylase, located in lumen of the ER and Golgi, decarboxylates UDPglucuronate to form UDP-xylose [10]. UDP-xylose is a precursor for the
synthesis of these glycosaminoglycans: heparin, heparin sulfate, chondroitin
sulfate and dermatan sulfate [9, 11]. UDP-glucuronate is also incorporated
into hyaluronan, another glycosaminoglycan, that is synthesized at the cell
surface and extruded into the extracellular space [8]. Glycosaminoglycans
may function independently as cellular coating or connective tissue or may be
attached to proteins in the late ER or Golgi [9]. Glycosaminoglycan synthesis
has been implicated in developmental defects, cancer progression, arthritis,
[12]and other disease states.
UDP-glucuronate contributes to protein glycosylation by providing
glucuronosyl units and xylose units for sugar transferases. Several types of
proteoglycans may be formed. Certain signaling proteins on the extracellular
surface are O-glucosylated and xylosated [13]. An example of this is the
xylosylation on O-glucose in EGF repeats on the Notch protein [10].
Additionally, synthesis of proteoglycans containing glycosaminoglycans in the
late ER and Golgi are initiated by transfer of a core tetrasacharride containing
xylose, two galactose units and a glucuronate to a serine in the protein [14,
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15]. After transfer of this priming linker, glycosaminoglycan biosynthesis
proceeds by addition of constituent sugars by sugar transferases.
Finally, UDP-glucuronate is the substrate for UDPglucuronosyltransferases, arguably the most important class of the phase II
drug metabolizing enzymes. Besides their critical role in detoxifying
xenobiotics, UDP-glucuronosyltransferases also allow cells to remove toxic
endobiotics [3, 4]. These enzymes attach the glucuronate moiety to the
compound, allowing the conjugate to be exported by multi-drug resistance
proteins in the plasma membrane. Thus, UDP-glucuronate is a cellular
metabolite with essential roles in the synthesis of glycosaminoglycans and
proteoglycans and in cellular detoxification.
1.3 UDP-glucose dehydrogenase
Human UDP-glucose dehydrogenase (UGDH) is an enzyme that
catalyzes the conversion of UDP-glucose to UDP-glucuronate by two
successive oxidation reactions. Much has been learned about the structure,
function and regulation of UDP-glucose dehydrogenase through in vitro
kinetic assays, x-ray crystallography and in vivo investigations.
The initial characterizations of UGDH were performed using S.
pyogenes and bovine liver UGDH, both enzymes that have a high similarity to
human UGDH. These early studies revealed a number of important features of
UGDH function. First of all, while UGDH was thought to exist as a homohexamer in humans and higher organisms, studies suggested that the
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hexamer contained only three active sites [16-18]. Also, it was recognized
early on that a catalytic cysteine was essential for the reaction, though it was
later realized that the cysteine is critical not in the first oxidation, but the
second [19-22]. The roles of other active site residues have been clarified
through mutagenesis, making possible the proposal of a reasonable reaction
mechanism involving a first oxidation to a thiohemiacetal intermediate and
further oxidation to a thioester intermediate before release of the product by
hydrolysis [8, 20, 22, 23].
The determination of the first crystal structure of UGDH, the S.
pyogenes structure, informed many of the kinetic mutagenesis studies. The
later availability of the C. elegans and human structures has confirmed the
close structural similarity of the human enzyme to the bacterial enzyme. The
available crystal structures highlight an interesting feature of the enzymes
that has been demonstrated by other methods as well: the bacterial enzyme is
a dimer, while the human enzyme is a hexamer.
In vivo studies of UGDH have focused primarily on regulation of the
enzyme at the transcriptional and post-translational levels, as well as, the
involvement of UGDH in epithelial cancers and development abnormalities.
UGDH is known to be transcriptionally up regulated in response to androgens
in various tissue types, including the prostate epithelium and breast cancer
cells [24-26]. It has also been shown that the UGDH promoter contains a
peroxisome proliferative receptor α (PPAR α) response element that mediates
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up regulation of UGDH in response to certain xenobiotics [27, 28]. At the posttranslational level, UGDH activity responds to a variety compounds. UDPxylose has long been recognized as an effective inhibitor of UGDH function
[29]. A recent study also implicates two polyphenols, gallic acid and quercetin,
in inhibition of UGDH activity in the cytosol [30].
UGDH has been associated with several pathological states in humans
and other species. The production of UDP-glucuronate for use in production
of extracellular-matrix polysaccharides impacts the progression of many
types of human epithelial cancers, including prostrate, breast, head and neck,
ventricle, colon, and pancreas cancer [31]. Additionally, several recent studies
in related organisms indicate UGDH has a significant, but poorly delineated,
role in development. The effects may be severe and cause embryonic lethality
as is the case when the sugarless gene of D. melanogaster contains certain
mutations [11] or less severe as is the case of mutations of the sqv-4 gene of C.
elegans that results in defects in vulval morphogenesis [32-34]. Mutation of
the jekyll gene, which encodes UDP-glucose dehydrogenase, of zebra fish
results in defects in heart valve formation [35]. These phenotypic
developmental problems seem to stem from problems with the formation of
proteoglycans and glycosaminoglycans, which require adequate levels of
UDP-glucuronate precursors.
In conclusion, UDP-glucose dehydrogenase is an important enzyme in
human development and in the progression of many types of human epithelial
cancers. Therefore, a more detailed understanding of the structure and
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function of this enzyme is essential. Recently, mutations in UGDH were
identified that are associated with congenital heart defects. These mutations
cause a change in oligomeric state of the enzyme from a hexamer to a dimer.
This shift in oligomeric state may explain the observed phenotype. Therefore,
understanding the differences in in vitro and in vivo activity and regulation
between the wild-type hexameric enzyme and the mutant dimeric enzymes is
essential to understanding the function of UGDH in development and may
provide insight into the role of UGDH in progression of epithelial cancers.
1.4 Glutathione
Like UDP-glucuronate, glutathione is an essential cellular metabolite,
not only because of its role in cellular detoxification, but also because of its
significant role as a reductive agent in the oxidative stress response and
maintenance of cellular redox homeostasis [5, 6, 36]. Glutathione is also
important for cysteine storage and transport and in altering sulfhydryl
accessibility to modulate signaling pathways and regulate enzyme activity
[38, 49, 90].
Glutathione is a tripeptide composed of glutamate, cysteine, and
glycine. It is synthesized by the sequential action of two enzymes, glutamate
cysteine ligase and glutathione synthetase [76, 97]. In the first and ratelimiting step of glutathione biosynthesis, glutamate cysteine ligase combines
cysteine and glycine to form

-glutamylcysteine in an ATP-dependent

reaction [37]. Next, glutathione synthetase, also requiring ATP, adds glycine

9
to form reduced glutathione [37, 38]. Oxidized glutathione is efficiently
reduced by glutathione reductase, a flavoprotein that uses NADPH as a
reductant, to maintain the cytosolic pool of glutathione in a reduced state
[39].
1.5 Glutamate Cysteine Ligase
Glutamate cysteine ligase (GCL) is a cytosolic protein responsible for
the first and rate-limiting step of glutathione biosynthesis. In humans and
other higher eukaryotes, GCL is composed of heavy catalytic subunit (73 KD)
and a light modifier subunit (30 KD) [40, 41]. The catalytic subunit is
sufficient for catalysis, while the modifier subunit is known to enhance the
activity of the catalytic subunit [44]. Additionally, the availability of the
modifier subunit contributes to regulation of enzyme activity by limiting
formation of the more active heterodimer. GCL is also regulated by feed-back
inhibition by the down-stream product, glutathione [42]. Glutamate cysteine
ligase has been widely characterized in a number of organisms.
Characterizations of glutamate cysteine ligase have revealed much about both
the complex reaction mechanism of the enzyme and the enzyme’s in vivo
functioning and regulation.
Three classes of GCL have been denominated based on sequence
conservation: the

-proteobacteria (group 1), the non-plant eukaryotes

(group 2), and the plants and α-proteobacteria (group 3). However, functional
characterizations and comparisons of the crystal structures of E.coli (Group1)
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and B. juncea (Group 3) with the recently published S. cerevisiae (group 2)
structure have indicated that the reaction mechanism between groups is
likely to be very similar [43-47]. Although the S. cerevisiae enzyme lacks a
modifier subunit, it has 45% sequence identity with the human catalytic
subunit [45]. Consequently, the S. cerevisiae structure has allowed for an
accurate model of the human enzyme catalytic subunit to be generated,
providing further insights into the catalytic mechanism.
The first step of the catalytic mechanism is an inline attack of the
phosphate of ATP by the

-carboxylate of glutamate to form a

-

-

glutamylphosphate intermediate [48]. Next, the α-amino group of cysteine
performs a nucleophilic attack, releasing the phosphate and forming the
product

-glutamylcysteine [49, 50]. The active site is particularly complex

due to the presence of three bound magnesium ions and three substrates:
glutamate, cysteine, and ATP. While debate exists over whether the
substrates are ordered or enter the active site randomly, the examination of
the human homology model based on the S. cerevisiae structure suggests, at
least, that glutamate enters the active site before ATP and cysteine [44].
Glutathione biosynthesis is carefully controlled by regulation of GCL
at multiple levels. At the post-translational level, glutathione acts as a
feedback inhibitor, while cysteine availability controls the overall rate of the
reaction [38, 42]. The association of the modifier subunit with the catalytic
subunit has a significant impact on activity; mice without the modifier
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subunit produce approximately 10-20% the normal amount of glutathione
[51]. Because GCLM availability limits heterodimer formation, increased
expression of the modifier subunit may enhance GCL activity [51-54].
Heterodimer formation appears to be regulated by one or more non-essential
disulfide bonds between the subunits and possibly by other post-translational
modifications or inter-subunit interactions [55, 56].
GCL activity is also increased in response to oxidative stress without
production of additional protein [51, 57, 58].
Additionally, glutamate cysteine ligase is subject to extensive
transcriptional regulation. The human GCLM and GCLC transcripts are
located on different chromosomes and are therefore subject to different
regulation [51, 59, 60]. Furthermore, the levels of GCLM and GCLC vary
widely in different human tissue types [61]. A number of transcriptional
regulatory factors have been identified that interact with GCL promoters.
These include Nrf2, AP1, AP3, NFκB, Maf proteins, JunD, Fra, and CREB [62].
Not surprisingly, glutamate cysteine ligase has been associated with
numerous diseases. Failure of glutathione production impacts the progression
of many diseases, including HIV, cancer, cystic fibrosis, Alzheimer’s disease
and Parkinson’s disease [63]. The importance of GCL to cellular homeostasis
and human health is highlighted by the fact that GCLC null mice are
embryonic lethal [64]. Interestingly, the absolute requirement for GCLC
appears to be satisfied even in the heterozygous state when dramatically
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lower levels of glutathione are produced. Recently, GCLC mutations have
been identified in individuals with hereditary glutathione deficiency, a
disease characterized by hemolytic anemia and sometimes accompanied by
neurological degeneration [65-69]. The erythrocyte glutathione levels in
individuals homozygous for the mutations were >10% of normal levels.
Because none of these mutations lie in the GCLC active site, it is not clear
why they cause such a dramatic reduction in glutathione levels. Further
studies of the mutations involved in this disease have the potential to lend
significant insight into GCLC function. This work details our investigation of
these GCLC mutants including assessment of glutathione production in GCLC
null mouse embryonic fibroblast cells and the GCLC null S. cerevisiae ∆GSH1
strain, as well as, kinetic characterizations in the presence and absence of the
modifier subunit.
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Chapter 2
Effects of altered oligomeric state on UDPglucose dehydrogenase function in vitro and in

vivo
Note: The results described in this chapter are being prepared for publication
and were completed by Melanie Neely Willis, Katie Easley, Alisha O’ Malley,
Joseph J. Barycki, Melanie A. Simpson, and members of Jeroen Bakker’s
laboratory.
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2.1 Introduction
UDP-glucose dehydrogenase catalyzes the conversion of UDP-glucose
to UDP-glucuronate via two successive oxidations, concomitantly converting
two molecules of NAD+ to NADH. UDP-glucuronate is an essential precursor
for protein glycosylation, production of extracellular matrix polysaccharides
and is necessary for cellular detoxification of xenobiotics and endobiotics via
UDP-glucuronosyltransferases [8, 20]. Availability of UDP-glucuronate and
UGDH expression have been implicated in a variety of epithelial cancers and
in developmental abnormalities [70-76]. Therefore, a detailed understanding
of the structure, function, and regulation of UGDH is essential.
While UDP-glucuronate is implicated in a variety of cellular processes,
recent advances in understanding both developmental abnormalities and
cancer progression associated with UGDH have highlighted the role of
hyaluronan, a key extracellular matrix polysaccharide in causation of both
processes [75]. The common link between development and cancer
progression is hyaluronan’s promotion of cell migration and proliferation.
While the types of cancer associated with increased hyaluronan production
include breast, head and neck, ventricle, colon, and pancreas cancer [31];
hyaluronan and UGDH have received significant attention in prostate cancer
progression, and UGDH has been named as a potential biomarker for prostate
cancer [77]. While much has already learned about UGDH, these advances
demonstrate the necessity of fully delineating the many factors that control
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UGDH function in the cell.
Detailed kinetic characterizations and mutation of key catalytic residues
by our lab and other groups have illuminated key steps in the reaction
mechanism of UGDH. These studies have been greatly aided by modeling the
human enzyme using the available S. pyogenes crystal structure (PDB ID:
1DLJ) and later, the C. elegans (PDB ID: 2O3J) and human crystal structures
(PDB ID: 2QE3). Early studies of the UGDH catalytic mechanism were made
using S. pyogenes and bovine liver enzyme. A Bi-Uni-Uni-Bi Ping Pong
mechanism was proposed in which the mechanism proceeded through an
UDP-aldehyde intermediate that was trapped by an active site lysine to form
a Schiff base intermediate [19, 78, 79]. An active site cysteine would then
attack the Schiff base, and the reaction would proceed to completion through
a thiohemiacetal intermediate, followed by further oxidation to a thioester
intermediate and hydrolysis to yield the product. Ultimately, the formation of
a Schiff base has been discredited [20, 23]. Kinetic data from our lab suggest
that in the human enzyme, K270 serves to position D280 in the active site,
which, in turn positions and activates a catalytic water molecule. The water
molecule may then directly abstract a proton from the 6’ hydroxyl of UDPglucose in the first oxidation step and be repolarized by K220. The repolarized
water might then activate the catalytic cysteine, C276, allowing attack to
form the thiohemiacetal intermediate. The K220 residue could then serve to
stabilize the oxyanion charge during formation of the thioester intermediate
and hydrolysis to yield the product, UDP-glucuronate [20, 22].
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In recent years, the knowledge of UDP-glucose dehydrogenase regulation
in vivo has rapidly advanced fueled, in part, by the association of UGDH with
various cancers and developmental aberrations. Several studies have reported
that the UGDH gene is under the control of the peroxisome proliferative
receptor α (PPAR α) response element, allowing an up-regulation of UGDH in
response to some xenobiotics [27, 28]. Similarly, UGDH has been
demonstrated to be up-regulated at the transcriptional level in response to
androgens in certain cancers [24-26]. These findings are not surprising
considering the key role UGDH plays in detoxification and epithelial cancer
progression, and future studies will likely expand and confirm the role of
transcriptional regulation in UGDH function and malfunction.
UGDH is also subject to extensive post-translational regulation,
including inhibition by UDP-xylose, quercetin, and gallic acid [9, 20, 21]. UDPxylose is produced from UDP-glucuronate in the ER and Golgi lumen, making
it a potent feedback inhibitor [Bakker]. Quercetin and gallic acid are both
members of the class of compounds known as polyphenols that have recently
been linked with prostate cancer tumor suppression [21]. While quercetin and
UDP-xylose have been proposed to be competitive inhibitors of UDP-glucose
in the enzyme active site, gallic acid was found to be a non-competitive
inhibitor [9, 21]. Additionally, UDP-xylose was shown to have effects on
allosterism, and quercetin was found to have mixed-type inhibition with
respect to NAD+ [20, 21]. A large-scale screen of chemicals by our lab revealed
a number of novel inhibitors that have yet to be characterized.
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Thus, it is possible that post-translational regulation of UGDH may
proceed by binding or interaction with sites on the surface of the protein,
distant from the enzyme active site. This possibility is significant because
bacterial forms of UGDH are dimeric, while human and other higher species
have a hexameric structure, a trimer of active dimers (Figure 2.1). In the
human enzyme, regulation may occur at sites not found in the dimeric
enzyme, such as at the dimer-dimer interface.

Figure 2.1. The human UDP-glucose dehydrogenase is a homohexamer. In humans and
other vertebrates, UGDH exists as a hexamer, a trimer of catalytically active dimers. Here
one dimer pair is shown in pink/red, one in blue/cyan and one in dark green/light green. PDB
ID: 2Q2E.

Furthermore, recent studies by our collaborator, Jeroen Bakker, have
revealed that certain mutations in human UGDH are associated with
congenital heart defects [80]. Further studies of these two mutants, UGDH
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E416D and UGDH R141C, confirmed the link between these mutations and
aberrant cardiac development in zebra fish. Knockdown of UGDH using a
morpholino in zebra fish embryos caused a dramatic increase in cardiac
edema. Yet, this phenotype was almost wholly abolished by addition of wildtype UGDH RNA. Partial rescue was observed when either UGDH E416D or
UGDH R141C RNA was added (Figure 2.2), indicating that there are in vivo
differences in the functioning of these two mutant UGDHs compared to wildtype.

Figure 2.1. Rescue of UGDH knockdown phenotype by RNA injection. Shown in the above
figure is the percentage of embryos developing an aberrant phenotype of cardiac edema (dark
grey bar) versus a wild-type phenotype (light grey bar) for each population. The different
populations are enumerated and correspond to each bar from left to right and indicate the
type of treatment. All embryos contain an UGDH morpholino to knockdown UGDH
expression. Selected populations were injected with human wild-type or UGDH E416D or
UGDH R141C RNA with a concentration of either 10 ng/µl or 50 ng/µl.
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Although these two mutations have a demonstrated phenotype in zebra
fish embryos, examination of the human crystal structure of UGDH reveals
that these two mutations are neither located in, nor are very close to the
enzyme active site. This observation raises the intriguing possibility that
rather than directly altering enzyme catalysis, these mutations may be
important to enzymatic regulation.
In conclusion, understanding the function of human UGDH has become
more urgent as UGDH has been associated with an ever-increasing number of
epithelial cancers and developmental defects. Initial characterizations of the
two UGDH clinical mutants have revealed in vivo differences in zebra fish
that are similar to a human phenotype associated with these mutations. Based
on the location of these two mutations distant from the enzyme active site,
these mutants may alter in vivo regulation rather than directly alter catalysis.
Determination of the in vivo effects of these mutants on UGDH activity is
essential to understanding the development of adverse phenotypes and
disease progression by providing insight into enzyme regulation and activity.
2.2 Materials & Methods
Generation of Mutant UGDH plasmids & Protein Expression and Purification
For expression in HEK 293 cells, the clinical and engineered dimer
point mutants of UGDH were generated from the wild-type UGDH-pIRES
construct using the Quik Change site-directed mutagenesis kit according to
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manufacture instructions (Stratagene). Sequences were verified by Eurofins
MWG Operon.
The human enzyme (PDB ID: 2Q2E) was examined in Chimera and
residues participating in hydrogen bonding at the dimer-dimer interface were
identified. Suitable candidates were chosen for mutagenesis directed at
disrupting the dimer-dimer interface and destabilizing hexamer structure.
The wild-type UGDH-pET28a construct was subjected to mutagenesis using
the Quik Change site-directed mutagenesis kit (Stratagene). Sequences were
verified by the University of Nebraska Genomics Core.
Proteins were expressed and purified as previously described [22].
Briefly, the N-terminal his-tagged plasmids for wild-type UGDH and each
mutant were transformed in Rosetta2 (DE3)pLysS E. coli cells (Novagen). The
next day, cells were grown in 2xTY media with 30 mg/L kanamycin at 37°C
until reaching an A600 of 0.6. The temperature was then reduced to 30°C, and
protein expression was induced by addition of a final concentration of 0.5mM
IPTG. After an hour, the temperature was reduced to 18°C, and the cells were
grown overnight. The next day, the cells were harvested by centrifugation.
The harvested cells were resuspended in 50mM sodium phosphate
buffer, 0.3M sodium chloride, 10mM imidazole, pH8 with 1mg/ml lysozyme.
The solution was then sonicated to ensure lysis. After centrifugation to
remove cellular debris, the supernatant was loaded onto a 5ml Ni-NTA
His•Bind column (Novagen) and purified according to the manufacturer’s
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instructions. The eluted protein was then dialyzed overnight at 4°C against
0.1M sodium phosphate, pH 7.4, flash frozen in liquid nitrogen, and stored at
-80°C.
Gel Filtration
The molecular weight of each mutant and wild-type UGDH was
determined by gel filtration chromatography to determine the oligomeric state
of each enzyme. Each enzyme was dialyzed in 0.15M sodium chloride, 50mM
tris, 1mM DTT, pH 7.4 and loaded onto a Superdex 200 HR 10/30 column (GE
Healthcare Lifesciences). The FPLC flow rate was 1 ml/min, and a protein
standard run was also performed using the following proteins: thyroglobin
(669 KD), ferritin (440 KD), aldolase (158 KD), ovalbumin (43 KD), ribosome
protein A (13.7 KD). The peaks for each wild-type and mutant UGDH were
compared to the standard proteins to determine the approximate molecular
weight and the corresponding oligomeric state of each species.
Analytic Ultra-centrifugation Sedimentation Velocity Experiments
Sedimentation velocity experiments were performed to confirm the
oligomeric state of the engineered dimer mutants. Purified wild-type, T325A
and E110A UGDH protein was dialyzed against 0.15M sodium chloride, 50
mM sodium phosphate buffer and diluted to 1 mg/ml. The mutant and wildtype enzymes were loaded into analytic cells and were centrifuged at 42,000
rpm for 18 hours in a Beckman Coulter ProteomeLab XL-1 centrifuge. A
preliminary examination of the data showed that the 1 mg/ml concentration
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was ideal, so further analysis was performed using this data. The data was
analyzed using SedFit [81] to find the molecular weights of the protein
complexes.
Kinetic Characterizations
The in vitro activity of each wild-type and mutant UGDH was
characterized using a standard kinetic assay as previously described [22]. For
each of the two substrates, NAD+ and UDP-glucose, the concentration of one
substrate was held constant at a saturating concentration, while the other
was varied from 1- 10mM to determine the kinetic constants, Km and Vmax. All
reactions were performed in a cuvette containing 500 µl of the substrates in
50mM sodium phosphate buffer. The reaction was initiated by the addition of
0.01mg of protein and monitored at 340nm for 1 minute to measure the
generation of NADH. The saturating concentration of NAD+ was 2mM, and
the saturating concentration of UDP-glucose was 200µM. All reactions were
performed in triplicate, and the change in absorbance over time was recorded.
The values were analyzed using Prism Graphpad software. The change in
absorbance was converted to mg/ml/min by multiplying the reaction volume
and dividing by the amount of protein and the extinction coefficient of NADH.
These values were plotted against concentration and fitted to a MichaelisMenten curve. The apparent Vmax and Km were determined from these curves
for each of the substrates.
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To determine the loss of activity over time of engineered dimer
mutants, aliquots of 1mg/ml UGDH T325A, UGDH E110A and wild-type
UGDH were placed at 37°C and periodically the activity of each was measured
using the standard kinetic assay described above. A saturating concentration
of UDP-glucose and NAD+ was used. The stability of the clinical dimer
mutants, UGDH E416D and UGDH R141C, was determined in a similar
manner except that 1:1 mixtures of each mutant with wild-type were also
evaluated.
Transient Transfections
To measure the concentration of UDP-glucuronate in vivo in
response to each mutant and wild-type UGDH protein, HEK293 cells were
transiently transfected to over-express each of the four dimeric mutants,
wild-type, and the blank GFP vector. Untransfected cells were also treated
similarly and used as a control. The HEK 293 cell line was chosen, both for
the ease of transfection and because previous work has demonstrated it
contains comparably low levels of UGDH enzyme. The cells were collected
and metabolite levels and protein expression were measured. In addition,
another set of transfections included wild-type UGDH, controls cells, the GFP
vector and a catalytically dead UGDH mutant previously characterized by
members of our lab, UGDH D280N.
HEK293 cells were cultured in DMEM 1X media with 10% fetal
bovine serum in 10 cm plates at 37°C and 5% carbon dioxide and transiently
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transfected using the calcium phosphate method with wild-type and mutant
UDP-glucose dehydrogenase in a GFP pIRES vector. The day before
transfection, the cells were split to 30% confluency. The day of the
transfection, the serum-containing media was removed and the cells were
washed twice with serum-free DMEM 1X. To transfect the cells, 1 X TBS was
added to the plasmid DNA and incubated for 5 minutes. 2.5 M calcium
phosphate was then added, and the mixture was incubated for 7 minutes. The
mixture was then added drop-wise to the cells. The cells were incubated
overnight and the media was removed and replaced with DMEM 1X + 10 %
fetal bovine serum.
The cells were harvested the next day by lifting with trypsin. The
cells were washed twice with cold PBS 1X. A quarter of the resuspended cells
were set aside for Western blotting and a sample was taken to count the cells
for each construct. The remaining cells were set aside for metabolite
measurements using HPLC. All cell samples were flash frozen in liquid
nitrogen and stored at -80°C.
Verification of Protein Expression by Western Blot
Western blotting was performed to verify and quantify expression of
UGDH for each transfected construct. Briefly, cells were lysed in RIPA buffer
with protease inhibitors, incubated on ice, and centrifuged to remove cellular
debris. A Bradford protein assay was performed to determine the protein
concentration of each sample [82]. The samples were then combined with
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loading buffer, heat denatured, and run on a 12% SDS-Page gel. The proteins
were transferred to a polyvinylidene fluoride membrane. The membrane was
simultaneously probed with anti-UGDH and anti-α-tubulin antibodies. An
Odyssey Infrared Imaging System (LI-COR) was used to detect fluorescent
secondary antibodies: Alexa Fluor 688 anti-mouse IgG (Invitrogen; β-tubulin)
and IRDye 800 anti-rabbit IgG (Rockland; UGDH). The intensity of each band
was measured and used in further analysis.
Measurement of UDP-glucuronate & related metabolites by HPLC
A method to prepare samples and perform HPLC was developed
based on previous methods [83, 84]. To perform HPLC quantification cells
were lysed by addition of 0.75M perchloric acid and proteins were removed
by centrifugation. The lysates were neutralized using 5M potassium
hydroxide, taking care not to raise the pH above ~6. Then, the lysates were
centrifuged to remove the salt. The sample was immediately loaded onto the
HPLC column.
The HPLC experiments were performed using a Waters spherisorb
SAX (strong anion exchanger) 5.0 µm, 4.6 mm x 150 mm column attached to a
Beckman System Gold Solvent Module and Detector 166 machine. Mili-Q
filtered water and 3.5 M ammonium phosphate were used as the mobile
phase. All buffers were filtered using a 0.22 µm filter (Whatman, Gmb.). Each
HPLC run consisted of a 5 minute water wash followed by a linear gradient of
ammonium phosphate from 0 to 100% over 30 minutes. The run was
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concluded by flushing with 100% ammonium phosphate before returning to
100% water over 5 minutes and then flushing with water for 10 minutes.
Peak data was recorded at 254 nm and 1 Mhz. Each set of transfectants was
run sequentially after first running a blank wash run and a run containing a
mixture of nucleotide standards. The nucleotide standard mix included the
following: 1mM NAD+, 1mM NADH, 1mM ATP, 1mM CTP, 1mMUTP, 1mM
GTP, 0.5M UDP-glucose, 0.5mM UDP-galactose, 0.5mM uridine
monophosphate, and 1mM UDP-glucuronate.
The data were analyzed as follows. Peaks were assigned to the
standard mixture by running each standard separately to determine retention
time and peak shape. The standard mixture of each data set was then used to
assign peaks to each sample run. A peak area report was generated using the
32 Karat Software, v. 5.0 (Beckman Coulter), and the area of each peak was
considered to be the raw metabolite measurement. These raw numbers were
normalized to total protein levels as determined by the Bradford assay. These
numbers were then entered into Prism Graphpad software to generate bar
charts to compare the relative concentration of each identified metabolite in
each of the transfectants.
2.3 Results
Protein Expression & Gel Filtration of the Clinical UGDH mutants
The mutant UGDH constructs were successfully generated from our
wild-type pET 28 construct. Each mutant UGDH was expressed and purified
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as soluble protein. Gel filtration chromatography, a typical final step in
protein purification protocols, yielded surprising information about UGDH
E416D and UGDH R141C. While the wild-type protein has previously been
observed by members of our lab to elute almost exclusively as a single peak of
~360 KD, both of the clinical mutants were found to have altered oligomeric
state compared to wild-type (Figure 2.3). UGDH E416D was found as a single
peak of ~120 KD, while UGDH R141C eluted as two nearly equal peaks, one
at ~120 KD and one at ~360 KD. Since each UGDH monomer has a molecular
weight of ~60 KD, a dimer would be expected to have a weight of ~120 KD
and a hexamer of ~360 KD. A standard curve of elution times versus the
standard protein molecular weight was created, and the equation of the line
was solved for the wild-type and mutant UGDH protein weights. This
confirmed that wild-type UGDH is a hexamer, UGDH E416D is a dimer, and
UGDH R141C exists in equilibrium between dimer and hexamer.
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Figure 2.2. Gel filtration of the clinical UGDH mutants. Shown are UGDH E416D (dashed
black), UGDH R141C (black), and wild-type UGDH (grey) size-exclusion chromatography gel
filtration traces. Wild-type UGDH and UGDH E416D each elute as a single peak representing
the hexameric and dimeric species, respectively. UGDH R141C elutes as two peaks,
demonstrating the presence of both the dimeric and the hexameric species.

Kinetic characterization of the clinical UGDH Mutants
These mutants, UGDH E416D and UGDH R141C, were further
characterized to reveal that their in vitro activity is nearly equivalent to wildtype activity, though R141C exhibits slightly diminished activity and tighter
binding of both substrates (Table 2.1). Bacterial species are known to have
dimeric UGDH, and it has been hypothesized that each of the dimers
composing the wild-type hexamer UGDH contained a functional active site.
Thus, it might be expected that a human dimer has similar activity to human
hexamer. Our results revealed that the clinical mutants have comparable in
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vitro activity compared the wild-type enzyme.
Table 2.1. Apparent kinetic constants for the clinical UGDH mutants.
Protein

NAD+

UDP-Glucose
Vmax
µmol/min/mg

Km
µM

Vmax
µmol/min/mg

Km
µM

Wild-type

1.011 +
0.0297

27.01+ 2.459

1.140 +
0.0235

576.5+ 29.26

E416D

1.017 +
0.0268

33.23 + 2.908

1.217 +
0.0403

576.7 + 46.99

R141C

0.547 +
0.0093

16.04 + 1.253

0.534 + 0.011 375.1 + 23.93

In vitro Stability Assays
Furthermore, in vitro assays were performed to determine the loss of
activity of each of the mutants at 37°C over time, with both mutant-only
samples and mutant mixed with wild-type samples to recapitulate the
heterozygous state (Figure 2.4).
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Figure 2.3. Loss of UGDH activity over time at 37°°C. Panel A displays the loss of activity
over time of UGDH R141C (triangle), a 1:1 mixture of wild-type and UGDH R141C (diamond),
and wild-type (square) as a function of activity measured by the standard kinetic assay
following NADH generation at 340 nm. Panel B represents this data as a loss in activity of
each enzyme or mixture where the initial activity is set equal to one for wild-type (square),
UGDH R141C (triangle), and UGDH R141C + wild-type (circle). Panel C displays the loss of
activity over time of UGDH E416D (triangle), a 1:1 mixture of wild-type and UGDH E416D
(diamond), and wild-type (square) as a function of activity measured by the standard kinetic
assay following NADH generation at 340 nm. Panel D represents this data as a loss in activity
of each enzyme or mixture where the initial activity is set equal to one for wild-type (square),
UGDH E416D (triangle), and UGDH E416D + wild-type (circle).

These studies indicate that UGDH E416D alone has a half-life similar to
wild-type UGDH. UGDH R141C, the mutant having mixed dimeric and
oligomeric state has a dramatically reduced half-life compared to wild-type
UGDH, which was slightly improved when mixed with wild-type UGDH.
However, the mixture of the dimeric UGDH E416D with wild-type UGDH
displays a reduced half-life compared to both UGDH E416D and wild-type
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UGDH alone. This result indicates that the mutant UGDH dimer may disturb
the ability of the wild-type dimers to trimerize into normal wild-type
hexamers. Thus, the clinical UGDH mutants may interfere with normal
protein stability and also may perturb allosteric regulation mechanisms in
vivo due to either dimeric character or to some other undiscovered property
of these two mutant proteins.
Creation of the Engineered UGDH Dimer Mutants
In order to distinguish between these two possibilities, we deemed it
prudent to create additional mutant UGDH enzymes existing wholly in the
dimeric state to clarify the effects of dimeric state on in vitro and in vivo
UGDH function. To do this, we examined the dimer-dimer interface of the
human UGDH crystal structure (PDB ID: 2Q2E)(Figure 2.5).
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Figure 2.4. The dimer-dimer interface of UDP-glucose dehydrogenase. Shown here is the
human hexamer turned on its side to view the dimer-dimer interface of the pink/red dimer
and the cyan/blue dimer. The light green/dark green dimer would be directly behind the
shown dimer-dimer pair.

Hydrogen bonds between adjacent dimers were identified and single
mutations were made in hopes of disrupting the dimer-dimer interface.
E110 was identified as a residue that hydrogen bonds with K329 on the
adjacent dimer. Additionally, E110 forms an inter-helical hydrogen bond with
R114. Thus, mutating E110 has the potential to not only disrupt the dimerdimer interface, but also, to compromise the structural stability of each
monomer. On the other hand, T325 does not directly bond with the adjacent
dimer. Instead, it participates in a network of hydrogen bonds between the
two dimers. T325 forms a hydrogen bond with K339, which forms a hydrogen
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bond with E110 in the adjacent dimer. Therefore, it is likely that mutating
T325 will disrupt the hydrogen bond between K339 and E110, though the
inter-helical bond between E110 AND R114 should remain intact. Both of
these residues, E110 and T325 were mutated to alanine, in order to neutralize
the charge-based interactions and not cause any unintended structural
perturbations. UGDH T325A and UGDH E110A were generated and
successfully purified as soluble proteins. Similar to the clinical mutants, these
mutations were distant from the enzyme active site (Figure 2.6).

Figure 2.5. Location of the Engineered Dimer Point Mutant Residues. Shown here is a
close-up of part of the dimer-dimer interface of UGDH. NAD+ is shown in a space-filling
model in the lower right side of the image. Residues participating in hydrogen bonds
disrupted by the mutations are shown, and hydrogen bonds are shown as black lines.

Gel filtration of the Engineered Dimer Mutants
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After protein expression and purification, we performed gel filtration
to determine whether the mutants eluted as hexamers, dimers, or in an
equilibrium between the two. Gel filtration confirmed the expected
hexameric state of wild-type UGDH and revealed that both the mutants,
UGDH E110A and UGDH T325A, were dimers rather than hexamers. Since
each UGDH monomer has a molecular weight of ~60 KD, a dimer would be
expected have a weight of ~120 KD and a hexamer of ~360 KD. The wildtype protein eluted between the aldolase (158 KD) and the ferritin (440 KD)
proteins, consistent with a molecular weight of ~360 KD. In contrast, both
the mutants eluted between ovalbumin (43 KD) and aldolase (158 KD),
consistent with a molecular weight of ~120 KD (Figure 2.7).
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Figure 2.6. panel A. Gel filtration of UGDH E110A. Shown are UGDH E110A (dashed red)
and the standard proteins (grey) size-exclusion chromatography gel filtration traces. The
standard proteins included thyroglobin (669 KD), ferritin (440 KD), aldolase (158 KD),
ovalbumin (43 KD), and ribosome protein A (13.7 KD). UGDH E110A eluted between
ovalbumin and aldolase, indicating a dimeric state. Panel B. Gel filtration of UGDH T325A.
Shown are UGDH T325A (dashed blue) and the standard proteins (grey) size-exclusion
chromatography gel filtration traces. The standard proteins included thyroglobin (669 KD),
ferritin (440 KD), aldolase (158 KD), ovalbumin (43 KD), and ribosome protein A (13.7 KD).
UGDH T325A eluted between ovalbumin and aldolase, indicating a dimeric state.

Analytic Ultra-centrifugation Sedimentation Velocity Experiments
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Analytic ultra-centrifugation sedimentation velocity experiments
also confirmed that the oligomeric state of each of the engineered mutants
was dimeric. Sedimentation velocity experiments have the advantage of both
determining the number of species present in a mixture and determining a
very accurate molecular weight for each species. Interestingly, the
sedimentation velocity experiments demonstrated that the oligomeric state
for wild-type was not wholly hexameric; a very small amount of the wildtype protein existed as a dimer. Similarly, the mutant UGDH T325A showed a
very small amount of protein in the hexameric state. In both cases, the
amount of protein in the minor species could be approximated at less than 5%
of the total. In contrast, the mutant UGDH E110A existed as a dimer, without
a hexameric peak.
Table 2.2. Molecular Weights Determined by Sedimentation Velocity
Protein

Molecular Weight (KD)

Wild-type

352

E110A

137

T325A

122

The molecular weights of the two dimer mutants varied slightly. UGDH
E110A had a molecular weight of 137 KD, while T325A had a molecular
weight of 122 KD. The minor peak of wild-type UGDH had a molecular weight
of 132 KD, corresponding to a small amount of dimer protein. The major peak
of wild-type UGDH was at 352 KD, while the minor peak of UDGH T325A was
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at 369 KD. These minor differences in weight between proteins having the
same amount of mass reflect the sensitivity of this technique to not only
mass, but also, to the shape of each protein as it travels across the solvent
during centrifugation. Thus, analytical ultra-centrifugation demonstrated
that the mutants UGDH E110A and UGDH T325A were dimers in contrast to
the wild-type, hexameric protein.
Kinetic Characterizations of the Engineered Dimer Mutants
After confirming that the engineered mutant UGDH proteins were,
indeed, dimers, we characterized them kinetically to determine if there were
significant differences between the in vitro activity of hexameric and dimeric
UGDH proteins. The kinetic data are summarized below (Table 2.3).
Table 2.3. Apparent Kinetic Constants for the Engineered Dimer
Mutants
Protein

UDP-Glucose

NAD+

Vmax
µmol/min/mg

Km
µM

Vmax
µmol/min/mg

Km
µM

Wild-type

.298 + .006

7.16 + .589

.320 + .008

354 + 30.8

E110A

.164 + .016

21.50 + 6.47

.167 + .010

186 + 58.3

T325A

.337 + .009

9.32 + .943

.322 + .010

331 + 38.0

The apparent Vmax values for the NAD+ measurement of wild-type and
UGDH T325A were in overlapping ranges, and the values for the UDP-glucose
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measurement were nearly that close. The apparent Km values for wild-type
UGDH and UGDH T325A were also very similar—the value for UDP-glucose
Km for UGDH T325A was ~28% greater than the value for wild-type UGDH,
and the values for NAD+ were in overlapping ranges.
However, UGDH E110A evidenced slight, but noticeable differences in
kinetic constants. The values for apparent Vmax for UGDH E110A were
approximately half those of wild-type UGDH for both the NAD+ and the UDPglucose measurements. Additionally, the apparent Km values were perturbed.
For the NAD+ measurement, the apparent Km of UGDH E110A was
approximately half of the wild-type UGDH value; while for the UDP-glucose
measurement, the apparent Km of UGDH E110A was approximately 3 times
the wild-type UGDH value. From the perspective of enzyme kinetics, these
values are still similar enough to indicate a highly similar level of activity
between both of the dimer mutants and wild-type UGDH. However, the
E110A mutant exhibits some noticeable, if slight differences from wild-type
UGDH and also has much larger error bars than the other two enzymes,
indicating that activity was less consistent between measurements.
Therefore, the kinetic characterizations reveal that the engineered dimer
mutants have almost equivalent activity to wild-type UGDH, though UGDH
E110A exhibits slightly different kinetic constants than the other enzymes.
In vitro Stability Assays
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We measured the activity of the engineered dimer mutants and wildtype UGDH after incubation at 37°C to determine if there were differences in
protein stability and activity at body temperature (Figure 2.8). Initially, wildtype and UGDH T325A activity were similar, and UGDH E110A activity was
approximately half that of wild-type, consistent with the detailed kinetic
characterizations. Interestingly, UGDH E110A activity dropped off almost
immediately, and after 6 hours, both mutants had dramatically reduced
activity compared to wild-type. By 10 hours, all three enzymes had severely
impaired activity. After 24 hours, the enzymes were inactive. These data
highlight the relative instability of the dimeric UGDH mutants compared to
wild-type UGDH, a difference that may have significant effects on in vivo
enzyme function.
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Figure 2.7. Loss of Activity at 37°°C. UGDH E110A, UGDH T325A and wild-type UGDH were
incubated at 37°C for 24 hours. Periodically, each protein was tested for activity using the
standard UGDH activity assay with NAD+ and UDP-glucose at saturating levels. Assays were
performed in triplicate.

Measurement of UDP-glucuronate & related metabolites by HPLC
HPLC metabolite analysis was performed to determine differences in
the in vivo functioning of the hexameric wild-type UGDH and the clinical and
engineered dimeric mutants. This method allowed measurement of both UDPglucose and UDP-glucuronate. Other related metabolites were also measured
including the nucleotide triphosphates, various UDP-sugars, NAD+, NADH
and uridine monophosphate, a breakdown product of UDP.
Initially, Western blot analysis revealed that the untransfected HEK293
cells and the vector-only GFP cells had very small amounts of UGDH,
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compared to the wild-type and mutant UGDH transfectants (Figure 2.9). No
notable differences in transfection efficiency or UGDH protein expression
between wild-type and the dimeric mutants were observed. However,
because our results indicate that in vivo protein stability may be
compromised in the dimeric UGDH mutants, the measured amount of UDPglucuronate was normalized to total protein levels, as determined by Bradford
assay, rather than to UGDH levels.

Figure 2.9. UGDH expression in transfected HEK293 cells. Shown here is a representative
Western blot to determine UGDH expression in transfected HEK293 cells. The first lane
contains the molecular weight marker. The second lane is purified, recombinant UGDH. A
green band, showing the anti-UGDH probe, appears at approximately 60KD, the expected
molecular weight of UGDH. The red bands show the anti-β-tubulin probe, used as a loading
control. The remaining lanes contain in ascending order: untransfected HEK293 cells, vectoronly GFP cells, UGDH D280N, wild-type UGDH, UGDH E110A, UGDH T325A, UGDH E416D
and UGDH R141C.

Surprisingly, none of the dimeric UGDH mutants showed any
significant differences in UDP-glucuronate levels compared to wild-type.
While significant differences in UDP-glucuronate levels were not found, we
did observe a slight increase in the amount of UDP-glucuronate in wild-type
UGDH compared to the mutants (Figure 2.10). Still, these differences were
slight and accompanied by large error bars, making any conclusions about in
vivo UGDH function based on UDP-glucuronate levels problematic. Therefore,
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the HPLC measurements of UDP-glucuronate levels did not demonstrate
significant differences between the dimeric mutants and wild-type UGDH.
Thus, measuring UDP-glucuronate levels as a measure of in vivo UGDH
enzyme function appears to have limited value. Examination of the levels of
UDP-glucose, NAD+, and NADH were similarly uninformative.

Figure 2.10. Levels of UDP-glucuronate in transfected HEK 293 cells. HEK 293 cells were
transiently transfected with each construct. UDP-glucuronate levels were measured by HPLC
and normalized to total protein levels. Wild-type level is set equal to one for ease of
comparison. Error bars represent the SEM of three replicates. Control and GFP values have
been omitted.

2.4 Discussion
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The recent identification of two mutations in UDP-glucose
dehydrogenase that are associated with human congenital heart defects and
an altered oligomeric state bring to light a little-contemplated aspect of in
vivo regulation that may have dramatic phenotypic consequences. UDPglucose dehydrogenase catalyzes the conversion of UDP-glucose to UDPglucuronate via two successive oxidations. UDP-glucuronate is an essential
precursor for protein glycosylation, production of extracellular matrix
polysaccharides and is necessary for cellular detoxification of xenobiotics and
endobiotics via UDP-glucuronosyltransferases [8, 20]. Availability of UDPglucuronate and UGDH expression have been implicated in a variety of
epithelial cancers and in developmental abnormalities [70-76].
The recently identified human UGDH mutants, UGDH E416D and
UGDH R141C, were found to exist wholly or partially as dimers, although this
change in oligomeric structure was found to not significantly impact in vitro
catalysis. In order to separate the effects of oligomeric state from other
impacts of these individual mutations, we endeavored to engineer and
characterize additional dimeric UGDH mutants. This work details our efforts
to detect in vivo differences in UGDH regulation due to oligomeric state by
measuring levels of UDP-glucuronate and other key metabolites in human
cells transfected with wild-type UGDH and the mutant UGDHs.
Initial Characterization of the Clinical UGDH Mutants
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The UDP-glucose dehydrogenase congenital heart defect mutations are
especially intriguing because they present such a dramatic developmental
phenotype based on a single amino acid substitution. While it is not
uncommon for an amino acid substitution to have a dramatic impact on
protein structure or function, the UGDH E416D and UGDH R141C mutations
are somewhat unique because they lie distant from the enzyme active site
and would not, on cursory examination, be expected have a significant impact
on either enzyme catalysis or structure. Thus, the question arises of how
these mutations affect UGDH structure and function, both in vitro and in
vivo.
Kinetic characterizations have revealed that these two mutants, UGDH
E416D and UGDH R141C, have essentially wild-type activity. Negligible
differences in apparent Km and Vmax were observed. Therefore, the activity
level of the mutant and wild-type enzymes in a physiological context, where
substrates are more limited than in our in vitro characterizations, would be
essentially the same unless other factors such as post-translational regulation
are perturbed.
A key observation of these mutants provided a possible explanation for
the observed phenotypic differences from wild-type. Gel filtration
demonstrated that each of the mutant enzymes had an altered oligomeric
state compared to the hexameric, wild-type enzyme. UGDH E416D eluted as a
single peak representing a molecular weight of ~120KD. Compared to the
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~360KD wild-type hexamer, this data clearly indicates that UGDH E416D
exists as a dimer. On the other hand, UGDH R141C eluted as two nearly equal
peaks of ~120KD and ~360KD, indicating that this mutant enzyme exists in
an equilibrium between the dimeric and hexameric state. In fact, it is likely
that at the presumably lower UGDH concentrations in the cell compared to
the gel filtration study, that this equilibrium may be further shifted toward
the dimeric state. Thus, while the clinical UGDH mutants do not significantly
impact in vitro activity, they have the effect of destabilizing the interactions
at the dimer-dimer interface, resulting in dimeric mutant enzymes.
It is well documented that many species suffer from developmental
abnormalities when UDP-glucose dehydrogenase is mutated [11]. The effects
may be severe and cause embryonic lethality as is the case when the sugarless
gene of D. melanogaster contains certain mutations [11] or less severe as is
the case of mutations of the sqv-4 gene of C. elegans that results in defects in
vulval morphogenesis [32-34]. Consistent with the work of our collaborator
with human UGDH in zebra fish, mutation of the jekyll gene, which encodes
UDP-glucose dehydrogenase, in zebra fish results in defects in heart valve
formation [35]. These phenotypic developmental problems seem to be related
to problems in synthesis of proteoglycans and glycosaminoglycans, which
require production of UDP-glucuronate precursors by UGDH.
In the case of the clinical mutants where it has been demonstrated that
in vitro activity of the mutant enzymes mimics activity of the wild-type

46
enzyme, some explanation is needed for the apparent defect in in vivo UGDH
function suggested by a phenotype that has been linked to impaired synthesis
of glycosaminoglycans. The observation that the clinical mutants have
dimeric rather than hexameric structure requires further investigation into
the impact of perturbation of oligomeric structure on the in vivo function of
the enzyme.
Creation and Initial Characterization of the UGDH Engineered Dimer
Mutants
To better study the effects of oligomeric state on in vivo UGDH
regulation, we created two more UGDH dimer mutants. The experiments with
the engineered dimer mutants essentially recapitulated those of the clinical
UGDH dimer mutants. Both engineered mutants were found to be primarily
dimeric in character. In vitro kinetic characterizations demonstrated that the
mutants, with slight variation for UGDH E110A, possessed essentially wildtype activity.
Initially, gel filtration and analytical ultra-centrifugation (AUC)
confirmed our success in creating dimeric UGDH mutants by mutating a
single amino acid residue for each mutant. The gel filtration profiles were
unambiguous and showed a single peak for each mutant between ovalbumin
(43 KD) and aldolase (158 KD) with a molecular weight of ~120 KD, consistent
with a dimer. On the other hand, the analytical ultra-centrifugation revealed
more details about the proteins. While both dimer mutants were found
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primarily in the dimeric state, UGDH T325A was found to have a very small
second peak at the molecular weight of hexameric UGDH. Interestingly, this
small amount (5% or less of the total) of hexameric T325A is not detectible by
gel filtration. Similarly, wild-type UGDH has, in addition to the hexameric
AUC peak, a small dimeric peak, a phenomena that has been observed
multiple times by members of our lab using gel filtration.
Another interesting aspect of the AUC data is that the two engineered
dimer mutants have slightly different molecular weights. UGDH E110A has a
molecular weight of 137 KD, while UGDH T325A has a molecular weight of
122 KD. This difference likely reflects the destabilized, floppy structure of
UGDH E110A compared to UGDH T325A, which would likely migrate more
slowly through the solvent due to minor differences in shape. While UGDH
E110 formed an intra-dimer hydrogen bond at the dimer interface, it also
formed a hydrogen bond with another residue on the same α-helix it is
positioned on (Figure 2.6). Thus, mutation to an alanine not only destabilizes
the hexameric structure, it also destabilizes each monomer.
The kinetic data also demonstrate that UGDH E110A may be slightly
destabilized by loss of this hydrogen bond. The mutant enzyme has
approximately half the apparent Vmax of wild-type, while the apparent Km for
UDP-glucose is increased ~ 2 fold and the apparent Km for NAD+ is decreased
by ~1/2. This, combined with the comparatively large error bars for UGDH
E110A, indicates that UGDH E110A has slightly erratic behavior due to slight
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internal destabilization. In contrast, UGDH T325A is similar to UGDH E416D
in that it has almost identical kinetic constants to wild-type UGDH.
Therefore, we successfully created two UGDH mutants that have dimeric
structure and wild-type in vitro activity. Thus, the engineered dimer mutants
provide an ideal compliment to our study of the effects of oligomeric
structure on in vivo UGDH function and regulation in the clinical UGDH
mutants.
Comparison of UDP-glucuronate levels between wild-type and mutant
UGDHs
Having assembled a set of UGDH dimer mutants, we directed our
efforts at measuring UDP-glucuronate levels in human cells having either
wild-type or mutant UGDH to evaluate the in vivo enzyme function. Many
methods have been used to study intercellular glucuronate levels. Originally,
thin layer chromatography allowed the identification and rough
quantification of UDP-glucuronate levels [85]. Newer methods have allowed
greater sensitivity and confidence in measurements, particularly high
performance liquid chromatography (HPLC) and mass spectrometry [3, 84, 8688]. While mass spectrometry is alluring, its use in metabolomics is in its
infancy, and only one report of its use to measure UDP-glucuronate exists
[88]. HPLC, on the other hand, has been widely used to measure UDPglucuronate levels using both strong anion exchange and reverse phase
methods [3, 84, 86, 87]. HPLC using a strong anion exchange column is
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particularly well suited to measure UDP-glucuronate levels, as well as UDPglucose, NAD+, NADH, and other related metabolites and breakdown
products. For these reasons, HPLC was utilized to assess in vivo UGDH
function.
Our results appear to reflect the complex nature of sugar metabolism in
the cell rather than the function of UGDH. The absolute value of UDPglucuronate measured was very low, with the peak being one of the smaller
peaks we were able to detect. The peak size and corresponding amount of
glucuronate did not appear to depend on whether we over-expressed wildtype or mutant UGDH in the cells. The remainder of the metabolite levels,
including those comparing the wild-type to the clinical mutants, varied less
than 2 fold with no consistent trends in product levels or substrate levels that
might be attributed to UGDH activity.
While it is disappointing that there is such little variance in UGDH
substrate and product levels, it is not entirely surprising. NAD+ and NADH
are cofactors in numerous reactions in the cell, so we would not necessarily
expect to see observable differences in these pools based on altering the
dynamic of a single enzyme’s activity. UDP-glucose is also a basic cellular
metabolite with many fates other than conversion to UDP-glucuronate. For
example, in the cytosol, besides conversion to UDP-glucuronate, UDP-glucose
may be epimerized to UDP-galactose, used to synthesize glycogen or directly
transported into the lumen of the ER or Golgi to participate in protein or lipid
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glycosylation [89-91]. While glucose is rarely found in mature glycoproteins, it
is used as a checkpoint sugar for proper glycoprotein folding before being
removed from the mature protein [91, 92]. Recently, it has also been shown
that significant levels of UDP-glucose may be released into the extracellular
space and may interact with the PY2 family of receptors as a part of
purinergic transmission [93-96]. With all of these fates of UDP-glucose,
perhaps conversion into UDP-glucuronate is minor pathway, and UGDH
activity has little overall impact on UDP-glucose levels in the cell.
A variety of reasons also exist why UDP-glucuronate levels did not
vary greatly based on UGDH activity in the cytosol. First of all, UDPglucuronate is used in the lumen of the ER or Golgi for protein glycosylation
or GAG synthesis. Numerous transporters have been identified that transport
UDP-glucuronate, and often other related sugars, from the cytosol into the ER
and Golgi [9, 97]. Additionally, depending on cell type and environmental
condition, a major fate of cytoplasmic UDP-glucuronate is conjugation to
xenobiotics by UDP-glucuronosyltransferases and subsequent export from the
cell [85, 98-100]. These mechanisms ensure that the levels of free UDPglucuronate remain low in the cytosol.
Furthermore, an ever-increasing body of evidence suggests that UGDH
activity is tightly regulated at both the transcriptional level and the posttranslational level. UGDH is known to be transcriptionally up regulated in
response to androgens in various tissue types, including the prostate
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epithelium and breast cancer cells [24-26]. It has also been shown that the
UGDH promoter contains a peroxisome proliferative receptor α (PPAR α)
response element that mediates up regulation of UGDH in response to certain
xenobiotics [27, 28].
At the post-translational level, and more directly relevant to our
results, UGDH activity responds to a variety compounds. UDP-xylose has long
been recognized as an effective inhibitor of UGDH function [29]. Reports
suggest that UGDH is competitively and allosterically regulated by UDPxylose [19, 29]. UDP-xylose is formed in the lumen of the Golgi and ER by
UDP-xylose synthase, also known as UDP-glucuronate decarboxylase [10]. A
recent study in Chinese hamster ovary cells indicates that UDP-xylose
transporters transport UDP-xylose to the cytosol to inhibit UGDH activity.
Consequently, loss of the UDP-xylose transporter resulted in a 200-fold
increase in cellular UDP-glucuronate levels [10]. Another recent study
implicates two polyphenols, gallic acid and quercetin, in inhibition of UGDH
activity in the cytosol [30]. Gallic acid was found to be a non-competitive
inhibitor, while quercetin showed competitive inhibition with respect to
UDP-glucose and mixed-type inhibition with respect to NAD+ [30]. A recent in
vitro screen performed for our laboratory also identified quercetin and several
other compounds having the typical polyphenol ring structure (along with
numerous other non-polyphenolic compounds) as being inhibitors of UGDH
activity.
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Because UDGH action is potently inhibited by a down-stream product,
UDP-xylose and by other naturally occurring compounds, UDP-glucuronate
production is likely to be limited. Additionally, due to the presumably rapid
siphoning of UDP-glucuronate to its multiple metabolic fates and the tight
regulation of UGDH activity by both transcriptional and post-translational
mechanisms, the levels of UDP-glucuronate in the cytosol remain at a
constant, low level, as reflected in our HPLC results.
However, in spite of the lack of meaningful differences in UDPglucuronate levels, the observed phenotype of heart valve development
defects associated with the clinical UGDH mutants can be at least partially
explained by differences in protein stability between wild-type UGDH and the
dimeric mutants. In the in vitro stability assays, all four dimer mutants lost
activity much more rapidly than the wild-type enzyme when incubated at
37°C. Thus, the dimer mutants may impact heart valve development by
producing less UDP-glucuronate even though a comparable amount of UGDH
is being produced by the cell.
In conclusion, the clinical and engineered UGDH dimer mutants were
used to examine differences in in vivo UGDH function resulting from loss of
hexameric structure. While the set of dimer mutants exhibited near wild-type
activity in vitro, significant differences in UDP-glucuronate levels were not
observed in HEK 293 cells. Despite this, the phenotype of heart development
defects associated with the UGDH clinical mutants is at least partially
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explained by a reduction in protein stability. Consequently, future efforts
should be directed at developing new methods of effectively measuring in
vivo UGDH activity and stability to confirm and quantify this proposed loss of
activity due to protein stability.
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Chapter 3
Enzymatic defects underlying hereditary
glutamate cysteine ligase deficiency are
mitigated by association of the catalytic and
regulatory subunits

Note: The work described in this chapter has been written up for publication.
The authors and title of the paper are:
Melanie Neely Willis, Yilin Liu, Ekaterina I. Biterova , Heejeong Kim,
Jaekwon Lee,
and Joseph J. Barycki. (2011) Enzymatic defects underlying hereditary
glutamate cysteine ligase deficiency are mitigated by association of the
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catalytic and regulatory subunits.
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3.1 Introduction
Glutathione (L-γ-glutamyl-L-cysteinyl-glycine; GSH) is an abundant
tripeptide critical for oxidative stress response and detoxification of
xenobiotics. It contributes to signalling pathways as well as the regulation of
enzymatic activity by altering the accessibility of protein sulfhydryl groups
[51, 62]. In addition to serving as a redox buffer, glutathione participates in
the storage and transport of cysteine [101] and select heavy metals [102]. The
diverse functions of glutathione are necessary for normal cellular processes
[101, 103-105], and disruption of glutathione homeostasis is associated with
numerous disease states [106, 107].
Glutathione is synthesized in humans by the sequential action of
glutamate cysteine ligase (GCL) and glutathione synthetase [93] [108]. GCL
catalyzes the formation of an amide linkage between the γ-carboxyl group of
glutamate and cysteine to form γ-glutamylcysteine, which is the rate-limiting
step in glutathione biosynthesis. In vertebrate systems, GCL typically exists
as a heterodimer consisting of a catalytic subunit (73 kDa) and a modifier
subunit (31 kDa). The catalytic subunit (GCLC) contains the active site while
the modifier subunit (GCLM) participates in regulation of enzymatic activity,
enhancing catalytic efficiency upon heterodimer formation [37]. GCLC null
mice are embryonic lethal [64, 105] while GCLM null mice are viable,
producing low levels of glutathione (10%-20% of normal levels), consistent
with a regulatory role [25].
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Several reports of hereditary GCL deficiency in humans have been
communicated [65-69]. The disease is marked by hemolytic anemia, low
levels of erythrocyte glutathione (typically < 10% of normal levels), and in
some cases, neurological disability. In the past decade, specific mutations in
the coding region of GCLC have been identified in patients with hereditary
GCL deficiency. Of the four clinical mutants identified thus far, three result
in a leucine substitution: proline 158 (Pro158Leu), histidine 370 (His370Leu),
or proline 414 (Pro414Leu). In each case, GCL activity was markedly reduced
in erythrocyte samples with corresponding reductions in glutathione levels.
However, the precise mechanism by which the mutation reduced enzymatic
activity was not identified beyond speculation that each mutation may
impact protein stability. A fourth mutation, resulting in the substitution of
an arginine residue at position 127 with a cysteine residue (Arg127Cys), has
been shown to directly impair enzymatic activity [66].
Recently, the crystal structure of the closely related Saccharomyces
cerevisiae GCL was reported, allowing a credible homology model of human
GCLC to be generated (Figure 1) [44]. Examination of the model provided
significant insights to the possible functions of each of these four residues. In
the current study, we used GCLC null mouse embryonic fibroblasts [105] and
S. cerevisiae devoid of glutamate cysteine ligase (∆gsh1) as model systems to
further examine the impacts of these clinical mutations on glutathione
production. In addition, we have kinetically characterized each of the human
GCLC clinical mutants, either alone or in complex with human GCLM. The
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results of these studies demonstrate the impact of the clinical mutations
responsible for hereditary GCL deficiency on the activity of the enzyme in
vitro and in vivo, as well as the critical role of the modifier subunit in
enhancing wild-type activity and restoring mutant activity.
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3.2 Materials and Methods
Plasmid construction and manipulations. The coding sequence
corresponding to GCLM (NM_002061.2) was amplified from a human cDNA
library incorporating the appropriate restriction sites into the designed
primers. For expression in S. cerevisiae, the insert was digested with BamH1
and Xho1 and ligated into a complementarily digested p416 ADH vector [109].
The bacterial construct was generated using a pET28a vector (Novagen) and
the restriction enzymes NheI and SalI. To generate expression vectors for
human GCLC (NM_001498.3), the coding sequence was inserted into a p415
ADH [109], a pCMV6-Entry (C-terminal Myc and DDK Tagged), or a pET24a
(Novagen) vector for expression in S. cerevisiae, mouse embryonic fibroblasts,
or E. coli, respectively. The point mutations, His370Leu, Pro158Leu,
Pro414Leu and Arg127Cys, were introduced using the QuikChange sitedirected mutagenesis kit (Stratagene) following the manufacturer's
instructions. All constructs were verified by sequencing (Eurofins MWG
Operon).
Mammalian tissue culture. A GCLC null mouse embryonic fibroblast cell line,
GCLC-/-, was generously provided by Dr. Zhengzheng Shi and cultured in
glutathione-containing media to 60% to 70% confluency as described
previously [105]. Cells were transiently transfected with wild-type GCLC and
each clinical mutant using FuGeneHD transfection reagent (Roche). After 24
hours, the media was replaced with glutathione-deficient media. Cells were
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cultured an additional 24 hours, released with trypsin, and washed with cold
1X PBS. The cells were counted and evaluated by Western Blot, using
polyclonal antibodies raised against full-length recombinant GCLC and GCLM
(Covance). Protein levels were normalized against β-tubulin, using an
Odyssey Infrared Imaging System (LI-COR) with Alexa Fluor 688 anti-mouse
IgG (Invitrogen; β-tubulin) and IRDye 800 anti-rabbit IgG (Rockland; GCLC
and GCLM) as secondary antibodies. Human GCLC was consistently observed
as a doublet with an approximate molecular weight of 75 kDa. Both bands
were used for quantification.
Determination of relative glutathione levels. To determine intercellular
glutathione levels, cells were lysed by mechanical disruption (BulletBlender;
Next Advance). After centrifugation, glutathione levels were quantified in the
cleared lysates using an enzymatic recycling method [110] that employs
glutathione reductase and 5,5'-dithio-bis-2-nitrobenzoic acid (Cayman
Chemical Company). Glutathione levels were normalized to GCLC protein
levels in the transfectants, with wild-type GCLC set equal to 1. Each
transfection was performed in triplicate and the mean value and standard
error for each mutant determined. Using Prism (Graphpad Software), an
ANOVA one-way test with Dunett’s Multiple Comparison Test was used to
determine the statistical significance of the lower glutathione levels observed
in the mutant transfectants.
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Yeast Spotting Assay. A BY4741 haploid S. cerevisiae strain deficient in
glutamate cysteine ligase (∆gsh1; Open Biosystems) requires exogenous
glutathione for growth, thus providing a powerful screening tool for the
formation of functional human GCL heterodimer. ∆gsh1 were transformed
with wild-type or mutant GCLC, with or without wild-type GCLM. An empty
p416ADH vector was co-transformed with the GCLC alone samples. The
transformations were performed as previously described [111]. Briefly, ∆gsh1
yeast were streaked on YPD (Yeast, Peptone and Dextrose, complete media)
plates and a single colony was selected and grown overnight in liquid culture.
Cells were harvested by centrifugation, washed with sterile water followed
by 1X Tris-EDTA/0.2M lithium acetate, and resuspended in 1X TrisEDTA/0.2M lithium acetate. After incubation for 15 minutes at 30°C, the
plasmid constructs and 40% PEG3350/TE/0.1 lithium acetate were added to
the cells. Cells were further incubated at 30°C for 20 minutes, followed by
heat shock at 42°C for 20 minutes. The transformed cells were plated on
uracil/leucine deficient plates (Synthetic Defined Media without leu and ura;
SD-leu,ura). GCLC only tranformants grew poorly in the absence of
glutathione and required the addition of 10 µM glutathione. GCLC with
GCLM transformants were restreaked and grown overnight in uracil/leucine
deficient media containing 1 µm glutathione. The next day, the yeast were
diluted to 0.2, 0.1, and 0.04 OD600 nm and spotted on uracil/leucine deficient
plates. Plates were monitored for growth for 72 hours. Data for the 36 hour
time point are presented.
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Protein expression and purification. The initial purification steps for
recombinant human GCLC and GCLM were comparable to those described for
S. cerevisiae GCL [44]. The GCLC or GCLM construct was used to transform
Escherichia coli Rosetta BL21(DE3) cells (Novagen). Cells were grown in
2xYT medium containing 50 αg ml−1 kanamycin at 30°C, and protein
production was induced by the addition of 500 αM isopropyl-1-thio-α-Dgalactopyranoside once the cells reached an A600nm of 0.6. After induction,
cultures were grown overnight at 18 °C. Cells were harvested by
centrifugation (20 min, 8000 × g, 4 °C) and stored at −80 °C. Frozen cell
pellets were thawed, resuspended in lysis buffer (50 mM sodium phosphate
buffer, pH 8.0, 300 mM NaCl, 0.2 mM protease inhibitor, 10 mM imidazole),
treated with lysozyme (1 mg/ml), and disrupted by sonication. Following
centrifugation to remove cellular debris (30 min, 20,000 × g, 4 °C), the
supernatant was loaded onto a HisTrap Chelating HP Column (GE Healthcare)
equilibrated with lysis buffer. The column was washed to baseline (A280nm),
and the remaining bound proteins were eluted using a linear imidazole
gradient (10–250 mM). For GCLM, appropriate fractions were pooled and
required no additional purification. GCLM was dialyzed against 20 mM Tris,
pH 7.4 containing 2 mM DTT, concentrated (Amicon stirred cell 8050, 10-kDa
cut-off), flash-frozen in liquid nitrogen, and stored at -80°C.
For GCLC, the protein was dialyzed against 50 mM Tris, pH 8.0
containing 2 mM DTT and subjected to ion-exchange chromatography using a
HiTrap Q FF column (GE Healthcare). Pooled fractions were then dialyzed
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against 50 mM Tris pH 7.4, 300 mM NaCl, 2 mM DTT, and subjected to sizeexclusion chromatography using a HiPrep 16/60 column Sephacryl S-100 HR
column. After pooling the appropriate fractions, GCLC was dialyzed against
20 mM Tris, pH 7.4 containing 2 mM DTT, concentrated (Amicon stirred cell
8050, 10-kDa cut-off), flash-frozen in liquid nitrogen, and stored at -80°C.
The holoenzyme complex was prepared by mixing purified GCLM and GCLC
at a ratio of 2:1. Initially, the wild-type heterodimer was isolated from
individual subunits by size-exclusion chromatography. Subsequent kinetic
studies indicated that the crude 2:1 GCLM/GCLC mixture accurately reflects
the catalytic efficiency of the purified heterodimer.
Kinetic assays. Enzymatic activity was measured using an indirect assay that
couples ADP production to NADH oxidation [41]. Each wild-type and mutant
GCLC was characterized alone or in complex with GCLM. The reaction
mixture contained 20 mM MgCl2, 5 mM phosphoenolpyruvic acid, 0.2 mM
NADH, and 4 units each of pyruvate kinase and lactate dehydrogenase (Sigma)
in 1 ml of buffer (100 mM Tris, pH 8.0, 150 mM KCl). To determine the
apparent kinetic constants, two of the substrates were held at or near
saturating concentrations and the third was varied. Typically, substrates
were held at concentration between 5 to 10-fold over the determined Km
value. However, considerable substrate inhibition was observed with excess
ATP present, similar to S. cerevisiae GCL [112], necessitating compromises
with respect to achieving complete saturation. Thus, ATP concentrations
were generally held at 3 to 5-fold over the determined Km value to limit
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substrate inhibition. Reduction in absorbance at 340 nm was followed over
three minutes, and measurements were determined in triplicate. MichaelisMenten kinetics were observed and apparent Km and Vmax values were
determined using Prism (Graph Pad Software). To examine protein stability,
human GCLC and GCLM/GCLC heterodimer (~ 1mg/mL) were incubated at
37°C. At the indicated time, an aliquot was removed and enzymatic activity
assayed. The mean and standard deviation for three replicates are presented
as relative activity versus time.
3.3 Results
Recapitulating homozygous mutations using a GCLC-deficient mammalian
model system. To begin examining the molecular basis of human GCLC
deficiency, embryonic fibroblasts obtained from GCLC null mice [105], GCLC-/-,
were transiently transfected with wild-type or mutant human GCLC.
Relative GCLC expression was quantified by western analysis and normalized
to β-tubulin. The hGCLC antibody, raised in rabbit against full length
recombinant hGCLC, readily detected wild-type and mutant proteins,
recognizing a doublet of approximately 75 kDa (Figure 3.1, inset). This
doublet has been observed previously [113, 114]. The precise identity of the
two species has not been demonstrated and it is unclear if these modifications
impact activity. However, several reports have suggested that GCLC may be
post-translationally modified [57, 113, 115]. The total glutathione
concentrations for the wild-type and mutant transfectants were measured
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and normalized to GCLC expression. As seen in Figure 3.1, the mean
glutathione level in untransfected cells was negligible. The nominal level
observed was the result of the exogenously supplied glutathione needed for
growth. The untransfected (<1%) and the Pro414Leu (~37%) transfected cells
had glutathione levels that were statistically reduced relative to wild-type
GCLC transfectants. Glutathione levels in the His370Leu, the Arg127Cys, and
the Pro158Leu transfectants were consistently reduced with levels between
60% and 70% of wild-type. These reproducible but modest reductions are in
contrast to more dramatic reductions observed in patient samples. This may
reflect differences in cellular GCLC:GCLM ratios as discussed below.

Figure 3.1. Glutathione production is reduced as a result of each of the four
clinical mutations. Embryonic fibroblasts obtained from GCLC null mice were
transiently transfected with wild-type or mutant human GCLC. Inset. hGCLC expression
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was monitored via Western blot analysis. Purified recombinant hGCLC was used as a
positive control (PC), and the non-transfected cells (NT) as a negative control. Main. Total
glutathione levels were measured and normalized to protein levels, using β-tubulin (not
shown) as a loading control. As discussed in the text, each mutant transfectant had reduced
levels of glutathione compared to wild-type, but only the non-transfected control and the
Pro414Leu transfectant were statistically lower.

Assessing the contributions of the regulatory subunit to GCL activity in an S.
cerevisiae model system. In mammalian systems, GCLC and GCLM are
differentially regulated and the relative ratio of the two proteins impacts
overall glutathione production [37, 61, 116]. The GCLC-null mouse embryonic
fibroblast cell line has a basal level of GCLM, and the heterodimer is the
major species observed when GCLC is transiently expressed (data not shown).
To assess the contributions of GCLM to the overall efficiency of the GCLC
mutants, it was necessary to find a system in which neither GCLC nor GCLM
is expressed. Since a double null GCLC/GCLM mammalian cell line is not yet
available, we identified S. cerevisiae as an alternative eukaryotic system. S.
cerevisiae has a single gene, gsh1, that is responsible for the synthesis of γglutamylcysteine and is closely related to human GCLC [117, 118]. The ∆gsh1
strain is unable to produce glutathione and grows only when supplied with an
exogenous source or when transfected with GCL. Thus, the ∆gsh1 yeast line
provides a reasonable system to examine the interplay between the GCLC and
GCLM subunits.
The ∆gsh1 yeast line was transformed with either wild-type or
mutant GCLC and plated on the appropriate selection media (SD-leu,ura).
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Overnight cultures were initiated but required the addition of 1µM
glutathione to obtain a reasonable growth rate. Several dilutions of each
overnight culture were spotted and monitored for growth. Although protein
expression levels for wild-type and GCLC mutants were comparable, wildtype GCLC could only weakly rescue the ∆gsh1 strain whereas none of the
mutant GCLC transformants grew (Figure 3.2), consistent with impaired
function. Co-expression of wild-type GCLC and GCLM resulted in robust
growth as a result of increased glutathione synthesis. Strikingly, coexpression of GCLM with Pro158Leu restored growth to levels comparable to
wild-type holoenzyme. To a lesser degree, the addition of GCLM partially
rescued the Arg127Cys and the His370Leu mutants. In contrast, the
Pro414Leu mutant, either alone or co-expressed with GCLM, did not grow
without the addition of reduced glutathione.
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Figure 3.2. The modifier subunit enhances the activity of wild-type and mutant hGCLC.
An S. cerevisiae strain deficient in glutamate cysteine ligase (∆GSH1) was transformed with
wild-type or mutant GCLC, with or without wild-type GCLM. An empty p416ADH vector
was co-transformed with the GCLC alone samples. Transformants were restreaked, grown
overnight in uracil/leucine deficient media, diluted to 0.2, 0.1, and 0.04 OD600 nm, spotted on
uracil/leucine deficient plates, and grown for 72 hours as described in the text. Wild-type
hGCLC alone could complement but more robust growth was observed when the holoenzyme
was present. None of the four mutant hGCLC transformants grew under these conditions.
However, formation of the holoenzyme restored near wild-type growth to Pro158Leu, and
permitted limited growth of Arg127Cys and His370Leu. However, addition of the modifier
subunit did not impact growth of the Pro414Leu mutant.

Characterization of recombinant human GCLC and GCLM. To further dissect
the impacts of human GCLC mutations on enzymatic function, each protein
was overexpressed in E. coli and purified to homogeneity (>95% pure based
on SDS-PAGE). Typical yields were ~50 mg/L of bacterial culture for human
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GCLM and ~10 mg/L of bacterial culture for human GCLC. Similar yields
were observed for each of the four clinical mutants, suggesting that overall
protein folding was not dramatically compromised by the mutations.
Apparent steady state kinetic constants for the catalytic subunit alone (Table
3.1) and the holoenzyme (Table 3.2) were determined using a coupled assay
system that monitored the production of ADP as a measure of enzymatic
activity.
Human GCLC had kinetic constants within the range of activities
reported previously [37, 55, 116, 119, 120]. The formation of the GCLM/GCLC
heterodimer increased Vmax while significantly reducing the apparent Km value
for ATP and to a lesser extent, the Km for glutamate (compare columns 1 and 3
in Tables 3.1 and 3.2) [116]. Noticeable substrate inhibition was observed at
increasing concentrations of cysteine or ATP, with estimated Ki values of 10 –
15 mM and 2 – 4 mM respectively (data not shown). The high concentrations
of ATP used for Km determinations consistently impacted the observed
enzymatic rates and accounted for the slight variability in the observed Vmax
values. Therefore, all comparisons of enzymatic activity used Vmax values
determined as a function of ATP concentration. The Pro158Leu mutant had
modest impact on the enzymatic activity of the catalytic subunit, whereas the
Arg127Cys GCLC mutant reduced Vmax by approximately 2-fold (Table 3.1).
Both mutations slightly increased the apparent Km for ATP. The His370Leu
and the Pro414Leu mutants exhibited severely impaired ATP binding, with a
near linear dependence of rate with respect to ATP concentration over the
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range tested (data not shown). Each mutant had an estimated Km value for
ATP greater than 20 mM, precluding the accurate determination of the
apparent kinetic constants for the remaining substrates.

Table 3.1. Apparent kinetic constants for wild-type and mutant human GCLC
Glutamate

Cysteine

Km

Vmax

Km

Vmax

Km

Vmax

(mM)

(µmol

(mM)

(µmol

(mM)

(µmol

min-1 mg-

min-1 mg-

min-1 mg-

1

1

1

)

Wild-type

1.14 ± .07

1.00 ±

)

0.10 ± .02

.019
Pro158Leu

0.68 ± .09

1.18 ±

1.38 ± .14

.544 ±

1.41 ±

)

2.68 ± .19

.057
0.08 ± .01

.005
Arg127Cys

ATP

1.78 ±

.047
3.57 ± .21

.047
0.05 ± .01

.019

.676 ±

1.43 ±

2.13 ±
.061

4.47 ± .56

.014

.837 ±
.057

His370Leu

NDa

ND

ND

ND

ND

ND

Pro414Leu

NDa

ND

ND

ND

ND

ND

a

The His370Leu and Pro414Leu mutations exhibit severely compromised ATP binding, as
reflected in highly elevated Km values for ATP. A lower estimate for each of the Km values is
approximately 20 mM, but may be considerably higher. This deficiency precluded further
detailed steady-state kinetic characterizations. At a given assay condition (5 mM ATP, 10
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mM Cys, 20 mM Glu, and 20 mM MgCl2), the His370Leu and Pro414Leu mutants have
activities that are 39% and 16% of wild-type GCLC respectively.

Formation of the activated heterodimer had differing effects on each of
the four clinical mutants. For the Pro158Leu mutant, addition of GCLM
increased Vmax by approximately 2-fold while significantly lowering the
apparent Km for ATP, similar to wild-type enzyme (Table 3.2). Modest effects
were observed with respect to Km values for the cysteine and glutamate
substrates. For the Arg127Cys mutation, formation of the GCLM/GCLC
heterodimer resulted in an increase in catalytic activity to a level comparable
to wild-type enzyme. Similarly, the addition of GCLM to either His370Leu or
Pro414Leu dramatically increased enzymatic activity to near wild-type levels
(Table 3.2), primarily by restoring robust binding of ATP. These in vitro
kinetic characterizations suggest that formation of the GCLM/GCLC
heterodimer would mitigate the detrimental effects of the GCLC clinical
mutations.
Table 3.2. Apparent kinetic constants for wild-type and mutant human
GCLC/GCLM complex
Glutamate

Cysteine

ATP

Km

Vmax

Km

Vmax

Km

Vmax

(mM)

(µmol

(mM)

(µmol

(mM)

(µmol

min-1 mg-

min-1 mg-

min-1 mg-
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1

1

)

Wild-type

0.46 ± .08

1.21 ±

0.07 ± .01

.061
Pro158Leu

0.65 ± .06

3.31 ±

1.38 ± .14

1.38 ±

0.17 ± .02

0.44 ±.04

1.22 ±.028

0.44 ± .08

3.17 ±

0.12 ± .01

1.34 ±

0.30 ±.05

1.44 ±

0.50 ± .09

0.77 ± .09

.913 ±
.038

0.17 ± .02

.619 ±
.024

1.67 ±
.170

0.26 ± .04

.047
Pro414Leu

4.77 ±
.440

.028
0.16 ± .02

2.38 ±
.260

.085

.052
His370Leu

1.23 ±

)

.043

.085
Arg127Cys

1

)

1.89 ±
.166

0.82 ± .29

1.71 ±
.426
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This concept was further supported by the enzymatic stability assays
(Figure 3.3). For the catalytic subunit alone, the wild-type enzyme retains
nearly full activity over a 24 hour period. In contrast, the Pro414Leu and the
His370Leu mutants lost more than 50% activity and the Arg127Cys and
Pro158Leu mutants lost more than 95% activity over the same time. Thus,
although the Pro414Leu and the His370Leu mutants were compromised
catalytically (Table 3.1), they were considerably more stable than the
Arg127Cys and Pro158Leu mutants, which had significantly higher enzymatic
activity. The addition of the modifier subunit dramatically increased protein
stability for the His370Leu, Arg127Cys, and Pro158Leu mutants. However,
formation of the Pro414Leu heterodimer provided only modest stabilization.
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Figure 3.3. Clinical mutations destabilize overall GCLC protein stability. Wild-type and
mutant GCLC were incubated at 37 °C and relative enzymatic activity was monitored as a
function of time. Bars are shaded as follows: Wild-type, black; Pro414Leu, grey; His370Leu,
hatched; Arg127Cys, dotted; Pro158Leu, white. Panel A. Human GCLC in the absence of
GCLM. Panel B. Human GCLC in the presence of GCLM.
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3.4 Discussion
Hereditary GCL deficiency presents a unique opportunity to examine
both the molecular mechanism of the disease and the importance of the
modifier subunit to the activity of the holoenzyme. Glutathione plays a
central role in protecting the cell from endogenous and exogenous threats
through oxidative stress remediation and xenobiotic detoxification. The
importance of GCL in catalyzing the first and rate-limiting step of glutathione
biosynthesis is widely recognized. However, the molecular details of catalysis
and the mechanism by which association of the catalytic and modifier
subunits enhances catalytic efficiency remain unclear. In the current study,
four GCLC missense mutations that result in hereditary glutathione deficiency
have been characterized. This work details the molecular basis of this disease
and demonstrates the critical role of the modifier subunit in rescuing the
activity of severely comprised mutant catalytic subunits.
To provide a quantitative assessment of the differences in glutathione
production between the GCLC mutants, we transiently transfected mouse
embryonic fibroblast cells from GCLC null mice (GCLC-/-) [105]. Consistent
with previous studies in which individual clinical mutations were identified
[65, 66, 68, 69], each of the four mutants had lower levels of total glutathione
compared to the wild-type GCLC transfectant (Figure 3.1). However, overall
reductions in glutathione levels were not as dramatic as observed in patient
samples. In part, this is may be due to the presence of significant quantities
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of GCLM in the GCLC-/- cells, which stimulates glutathione production. GCLM
levels were not reported for the patient samples and it is possible that GCLM
levels are considerably higher in the cell culture model. However, the overall
trend in relative glutathione levels is consistent with previous clinical
studies.
To assess the contributions of GCLM to catalytic activity in a
eukaryotic system, an S. cerevisiae model was employed. S. cerevisiae has a
single gene responsible for the efficient biosynthesis of γ-glutamylcysteine,
gsh1, and lacks a functional equivalent of GCLM [118]. ∆gsh1 yeast
transformed with either GCLC alone or with both GCLC and GCLM grew on
glutathione deficient media, though the presence of GCLM conferred a
distinct growth advantage (Figure 3.2). These results are consistent with
observations in mice that GCLM is non-essential but enhances glutathione
production [104, 116]. Unlike wild-type GCLC, none of the four mutant GCLC
subunits identified in hereditary GCL deficiency patients grew in the absence
of GCLM, suggesting that overall cellular glutathione levels were likely below
1 µM, the minimal level of exogenous glutathione needed to confer growth to
the ∆gsh1 strain. In contrast, the presence of GCLM was able to restore
growth to three (His370Leu, Pro158Leu, Arg127Cys) of the mutant GCLC
transformants. The fourth mutant, Pro414Leu, failed to grow, and is
consistent with the more dramatic reduction in glutathione levels observed in
the GCLC-/- cell culture system (Figure 3.1). Thus, the role of the modifier
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subunit in enhancing catalytic activity appears to be particularly relevant in
cases where the catalytic subunit is compromised by a mutation.
Based on the observed differences between wild-type and mutant GCLC
in the ∆gsh1 yeast and GCLC-/- cells, we performed in vitro kinetic
characterizations in the absence (Table 3.1) and presence (Table 3.2) of the
modifier subunit to further understand the impact of each amino acid
mutation on enzyme catalysis and the molecular basis of disease. Consistent
with earlier observations with mouse GCL [116], our kinetic studies
demonstrate that the modifier subunit enhances the activity of the wild-type
subunit and dramatically lowers the Km for ATP. Strikingly, each of the
mutant GCLC proteins also displayed increased activity when combined with
GCLM, often attaining apparent constants comparable to the wild-type
enzyme (Compare Tables 3.1 and 3.2). In addition, heterodimer formation
improved the protein stability of each mutant (Figure 3.3). This suggests that
therapeutics that promote heterodimer formation in vivo or can mimic the
effects of modifier subunit binding may provide effective treatments for GCL
deficiency.
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Figure 3.4. Homology model of human glutamate cysteine ligase reveals the locations
of the four clinical mutations. The overall model of hGCLC is shown in ribbon
representation with β-strands colored in green, α-helices in blue, and loop regions in grey.
ADP and the transition state analogue, phosphorylated BSO (BSO-P), were docked into the
previously described model and are shown in ball and stick representation. Carbon atoms
colored in grey, oxygen atoms in red, sulfur atoms in yellow, nitrogen atoms in blue,
phosphorus in orange, and magnesium atoms in purple. The locations of the four clinical
mutations are highlighted, with carbon atoms colored in purple.

To understand the molecular basis of the observed kinetic and
phenotypic differences, we examined a homology model of human GCLC
(Figures 3.4 and 3.5) [44]. Previous modeling studies suggested that Arg 127
was located proximal to the substrate binding pocket, in a surface exposed
pocket [66]. However, these studies necessarily used a more distant
homologue as a template. Based on the x-ray structure of the closely related
S. cerevisiae GCL, a more robust human GCLC homology model was
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generated. In our model, Arg 127 is adjacent to the enzyme active site and
forms a salt-bridge with Asp 49, as well as a hydrogen bond with the
backbone carbonyl oxygen of Gly 104 (Figure 3.5A). Replacement of Arg 127
with a cysteine residue would disrupt this hydrogen bond network and
negatively impact catalysis both directly and indirectly. The backbone
carbonyl of Asp 49 is positioned to form a hydrogen bond with the 3′ hydroxyl
group of the ATP ribose. In addition, the β-strands containing Asp 49 and Gly
104 contain conserved glutamate residues critical to function. Disruption of
the Arg 127/Asp 49 salt bridge may lead to displacement of Glu 50 and Glu 52,
whereas eliminating the Arg 127/Gly 104 hydrogen bond could alter the
position of Glu 103. Each of these glutamate residues is involved in
magnesium coordination and substrate binding, and is critical for efficient
catalysis. Importantly, each of these proposed interactions is conserved in
the S. cerevisiae GCL template [44, 112].
The predicted impacts of the Arg127Cys mutation based on modeling
studies are supported by the available kinetic data. The initial report of this
clinical mutation indicated that the Arg127Cys mutant alone had <5% of
wild-type activity and bound glutamate and aminobutyrate, a cysteine
surrogate, more efficiently [66]. However, ATP binding was not examined. In
the current study, the Arg127Cys mutant in the absence of GCLM has an
elevated Km for ATP and a reduced Vmax as compared to wild-type GCLC alone
(Table 3.1), consistent with a more modest perturbation of the active site
architecture. Differences in assay conditions including assay temperature,
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substrate concentrations used, and the location of the engineered histidine tag
used for affinity purification may account for these differences. Nonetheless,
both reports demonstrate that the Arg127Cys negatively impacts catalysis.
Addition of GCLM to Arg127Cys restores enzymatic activity, with the mutant
holoenzyme exhibiting kinetic constants comparable to the wild-type
heterodimer (Table 3.2). This restoration of Arg127Cys activity by GCLM is
also evident in the yeast spotting assay in which Arg127Cys alone did not
grow, but addition of GCLM permitted growth, albeit at a reduced level
compared to wild-type (Figure 3.1). Similarly, the levels of glutathione found
in the GCLC-/- cell line transiently transfected with Arg127Cys were
consistently lower than wild-type glutathione levels (Figure 3.1). These
observations indicate that the Arg127Cys mutation destabilizes overall
protein structure, and that the additional stabilization afforded by
heterodimer formation can offset these negative consequences (Figure 3.3).
Thus, the addition of the modifier subunit can partially restore Arg127Cys
activity, both in vitro and in vivo.
Our model of human GCLC suggests that histidine 370 and proline 414
are located in close proximity to the ATP-binding region of the active site
(Figure 3.5B). Specifically, both residues appear to be involved in the
positioning of a β-strand containing Lys 412, which participates in an
extensive hydrogen bond network that is involved in ATP binding and proper
orientation of active site residues. The mutation of proline 414 to leucine
probably destabilizes a rigid series of proline residues connecting two beta
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strands resulting in reduction of ATP binding. This is in contrast to a
previously reported model that indicated Pro 414 was located at the end of an
α-helix, considerably removed from the enzyme active site [68]. Histidine 370
appears to participate in an extensive hydrogen bond network with tyrosine
266 and glutamine 402 near the phosphate coordination region. Both
His370Leu and Pro414Leu have compromised enzymatic activity in the
absence of GCLM, primarily as a consequence of poor ATP binding (Table 3.1).
However, addition of GCLM to either mutant rescues enzyme activity through
restoration of efficient ATP binding (Table 3.2) and to different extents,
improving overall protein stability (Figure 3.3). The His370Leu mutant
regains near full activity whereas the Pro414Leu mutant has somewhat
reduced activity. In support of this interpretation, initial studies with a
Lys412Ala mutant indicate that the enzyme has severely compromised
catalytic activity (MNW and JJB, unpublished observation). Overall, our data
suggest that formation of the heterodimer can compensate for these
destabilizing mutations by ordering the enzyme active site.
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Figure 3.5. Clinical mutations disrupt hydrogen bond networks that stabilize the
enzyme active site. The figure illustrates the hydrogen bond networks centered about three
of the clinical point mutations. Atoms are colored as in Figure 10 with potential hydrogen
bonds illustrated as solid black lines. Panel A. Arg 127 stabilizes two β-strands within the
active site, forming a salt bridge with Asp 49 and a hydrogen bond with the backbone
carbonyl of Gly 104. Panel B. His 370 is involved in a hydrogen bond network that positions
a β-strand that contains Lys 412. Pro 414 is the second of four proline residues in a rigid loop
immediately adjacent to Lys 412, which is involved in orienting the β-phosphate of ATP.
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These kinetic characterizations agree with the described cell culture
studies. Particularly striking is the observation that the most kinetically
crippled mutant, Pro414Leu (Table 3.1), is also the only mutant that failed to
grow in combination with GCLM in the yeast spotting assay and that had
statistically lower glutathione levels than wild-type in the GCLC-/- cell-based
assays. Intriguingly, the only reported clinical case of GCL deficiency with
the Pro414Leu mutation was accompanied by progressive motor neuropathy
of the lower extremities and psychomotor development [68]. Although other
cases of neuropathy have been found in patients with GCL deficiency, the
suggestion that the Pro414Leu mutation may lead to a more severe version of
the disease is consistent with our experimental results.
Proline 158 lies on a solvent-exposed loop far from the enzyme active
site. Its remote location and lack of sequence conservation suggests that a
mutation of proline 158 to leucine would not have dramatic impact on
enzyme catalysis. Our kinetic studies show that this mutation causes a slight,
but distinct, increase in GCLC activity in both the catalytic only and
holoenzyme forms compared to wild-type (Tables 3.1 and 3.2). In contrast,
the Pro158Leu mutant exhibited reduced glutathione levels in the GCLC-/- cell
line and could not complement the ∆gsh1strain, unless the modifier subunit
was also present. Once the holoenzyme was formed, the growth of Pro158Leu
appeared very similar to that of wild-type GCLC/GCLM heterodimer. This
phenotype is very similar to that of Cys152Ala, another mutant in this region
of the enzyme recently characterized by our lab (YL and JJB, manuscript in

84
preparation), suggesting that this region of GCLC is particularly sensitive to
perturbations.
The apparent inconsistency between limited effect of the clinical
mutations on apparent kinetic constants and the significant reduction in
glutathione in the yeast and mouse embryonic fibroblast models can be
reconciled if cellular protein stability is considered (Figure 3.3). The
Pro158Leu mutant alone was the least stable enzyme of those tested.
However, once the GCLM subunit was added, protein stability improved
dramatically, to levels comparable to wild-type heterodimer. This suggests
that the mutant catalytic subunit alone is less persistent in vivo perhaps due
to decreased stability or increased turnover. Formation of the heterodimer
stabilizes the Pro158Leu mutant and allows for the production of glutathione.
This is supported by recent studies of the Pro158Leu mutant in which specific
activities were measured at 37ºC [121]. A dramatic decrease in Pro158Leu
activity in the absence of GCLM was observed (<10% activity) as compared to
wild-type enzyme. The addition of GCLM significantly stimulated activity,
such that the mutant heterodimer was only approximately 4-fold less active
than the wild-type holoenzyme.
Dalton and co-workers have demonstrated that erythrocyte glutathione
levels are low in GCLM-/- mice and that GCLM is limiting in most tissues [104,
116]. Depending on tissue type, GCLC to GCLM ratios of 1.5 to 7 were
typically observed, but the study did not specifically examine the GCLC/GCLM
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ratio in erythrocytes. However, the observed manifestations of hereditary
GCL deficiency combined with the studies reported herein are consistent with
limiting GCLM in red blood cells. Patients with GCLC deficiency have very
low levels of erythrocyte glutathione and exhibit hemolytic anemia,
indicating that glutathione biosynthesis is compromised most notably in
erythrocytes, cells in which it is needed to effectively combat oxidative stress.
Our kinetic data indicate that for each mutant, formation of the heterodimer
dramatically restores GCL activity. These observations suggest that GCLM
may be limiting in red blood cells, such that near wild-type enzymatic
activity is not realized. In addition, the mutant GCLC may not persist
throughout the approximately 120 day lifespan of an erythrocyte [122] when
GCLM is limiting.
In summary, our characterizations of the four clinical mutations
identified in hereditary GCL deficiency reveal disparate molecular
mechanisms that impair glutathione production by reducing the activity of
the catalytic subunit of GCL. The critical role of the modifier subunit in
enhancing activity of the catalytic subunit is evident in the ability of the
modifier subunit to rescue activity of the mutant catalytic enzymes in both
our in vitro and in vivo studies. Therapeutic strategies that stimulate GCLM
production, stabilize the heterodimer, or mimic heterodimer formation may
be effective in the treatment of this disease.

86

87

Chapter 4
Conclusions and future directions
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4.1 Conclusions
UDP-glucose dehydrogenase
UDP-glucose dehydrogenase catalyzes the conversion of
UDP-glucose to UDP-glucuronate via two successive oxidations,
concomitantly converting two molecules of NAD+ to NADH. UDP-glucuronate
is an essential precursor for protein glycosylation, production of extracellular
matrix proteins and is necessary for cellular detoxification of xenobiotics and
endobiotics via UDP-glucuronosyltransferases [8, 20]. Availability of UDPglucuronate and UGDH expression have been implicated in a variety of
epithelial cancers and in developmental abnormalities [70-76]. Therefore, a
detailed understanding of the structure, function, and regulation of UGDH is
essential.
While UDP-glucuronate is implicated in a variety of cellular processes,
recent advances in understanding both developmental abnormalities and
cancer progression associated with UGDH have highlighted the role of
hyaluronan, a key extracellular matrix polysaccharide in causation of both
processes [75]. The common link between development and cancer
progression appears to be hyaluronan’s promotion of cell migration and
proliferation. While the types of cancer associated with increased hyaluronan
production include breast, head and neck, ventricle, colon, and pancreas
cancer [31], hyaluronan and UGDH have received significant attention in
prostate cancer progression, and UGDH has been named as a potential

89
biomarker for prostate cancer [77]. While much has already learned about
UGDH, these advances demonstrate the necessity of fully delineating the
many factors that control UGDH function in the cell.
Consequently, in the past decades, detailed studies have illuminated
the key details of the mechanism of UGDH. More recently, advances have
been made in understanding the transcriptional and post-translational
regulation of UGDH. Indeed, many of these regulatory mechanisms are
congruent with our current understanding of the important roles UGDH
enacts in cellular metabolism. For example, UGDH is post-translationally
inhibited by the downstream product UDP-xylose, which is formed in the ER
or Golgi lumen by UDP-glucuronate decarboxylase, allowing feedback
inhibition by the glycosylation pathway [10]. Likewise, transcriptional upregulation of UGDH by certain xenobiotics integrates UDP-glucuronate
production and cellular detoxification [28]. However, less is known about
other regulators, such as gallic acid and quercetin [30]. Neither is it known
whether these in vivo regulators are impacted by the oligomeric structure of
UGDH.
Recently identified human UGDH mutants, E416D and R141C, were
found to exist wholly or partially as dimers, although wild-type UGDH is a
hexamer. This change in oligomeric structure was found to not significantly
impact in vitro catalysis. However, these UGDH mutations were associated
with congenital heart defects in humans and defects in cardiac valve
formation in zebrafish. Therefore, we endeavored to discover whether
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oligomeric state alone impacted in vivo UGDH function by measuring UDPglucuronate levels from HEK293 cells transiently transfected with mutant
and wild-type UGDH. In order to separate effects of the individual mutations
from those dependent on oligomeric state, we engineered two more UGDH
mutants that were exclusively dimers: UGDH E110A and UGDH T325A.
Presumably due to the tight regulation of UGDH and its participation
in many diverse cellular processes, UDP-glucuronate levels were maintained
at a low level in the cell compared to other related metabolites. No significant
differences were found in levels of UDP-glucuronate, UDP-glucose, NAD+, or
NADH between wild-type UGDH and any of the mutant UGDH proteins. Thus,
the development of alternative methods to measure UDP-glucuronate
synthesis in vivo are necessary.
In spite of this, the in vitro stability assays demonstrate that UDPglucose dehydrogenase activity is reduced in the dimeric mutants at 37°C. A
destabilization of protein structure and activity in the clinical mutants
provides a plausible explanation for the observed phenotype of developmental
heart defects. During development, the demand for hyaluronan and UDPglucuronate are elevated, so any alteration of protein stability might produce
a dramatic effect not detected in the in vivo cell culture assays we performed.
With the development of better detection methods, perhaps differences in
UGDH function due to protein stability could be measured even in a cell
culture model.
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Glutamate Cysteine Ligase
Glutamate cysteine ligase (GCL) is a cytosolic protein responsible for
the first and rate-limiting step of glutathione biosynthesis [37, 108].
Glutamate cysteine ligase catalyzes the formation of an amide linkage
between the γ-carboxyl group of glutamate and cysteine to form γglutamylcysteine [37, 50]. In humans and other higher eukaryotes, GCL is
composed of heavy catalytic subunit (73 KD) and a light modifier subunit (30
KD). The catalytic subunit is sufficient for catalysis, while the modifier
subunit is known to enhance the activity of the catalytic subunit [40, 41].
Glutathione (L-γ-glutamyl-L-cysteinyl-glycine; GSH) is an abundant
tripeptide critical for oxidative stress response and detoxification of
xenobiotics. It contributes to signalling pathways as well as the regulation of
enzymatic function by altering the accessibility of protein sulfhydryl groups
[51, 80] and participates in the storage and transport of cysteine [101] and
select heavy metals [102]. The diverse functions of glutathione are necessary
for normal cellular function [101, 103-105], with disruption of glutathione
homeostasis associated with numerous disease states, including cancer,
neurodegenerative diseases, anemia, cystic fibrosis, HIV, and aging [106, 107].
Recently, four single amino acid mutations in the catalytic subunit
of glutamate cysteine ligase were identified in patients with hereditary
glutathione deficiency, a disease characterized by extremely low levels of
erythrocyte glutathione, hemolytic anemia and neurologic problems [65-69].
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We comprehensively characterized these mutant GCLC subunits, in vitro and
in two eukaryotic systems to determine the molecular basis for disease.
By measuring the glutathione produced by each mutant GCLC in
combination with the modifier subunit in mouse embryonic fibroblast cells,
we demonstrated that each of the GCLC clinical mutants has lower
glutathione levels than wild-type. Our yeast transformations of each mutant
GCLC, both with and without the modifier subunit, highlighted the
requirement of the modifier subunit for glutathione production in the mutant
GCLC transformants. The in vitro kinetic characterizations confirmed that for
3 of the clinical mutants—P414L, H370L and R127C—the addition of the
modifier subunit dramatically rescues impaired catalytic function.
Curiously, the fourth mutant, P158L, has distinctively higher activity
than wild-type in both the catalytic only and holoenzyme assays. In spite of
this, GCLC P158L failed to grow without addition of the modifier subunit in
yeast and had a lower level of glutathione compared to wild-type in the
presence of the modifier subunit in the mouse embryonic fibroblast cells. This
paradox, combined with the results from the other 3 mutants showing more
dramatic in vivo phenotypes than the kinetic data alone would suggest,
indicate that some other factor affects in vivo functioning of the mutant
enzymes compared to the wild-type. The in vitro protein stability assay
demonstrated that each of the four GCLC mutants suffered from a dramatic
loss of activity over 24 hours, while the wild-type enzyme retained full
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activity, suggesting that the in vivo functioning of the GCLC mutants is
negatively impacted by reduced protein stability. Thus, our studies of the
GCLC clinical mutants indicate both the impaired catalytic function
underlying hereditary glutathione deficiency and the critical role of modifier
subunit in rescuing the function of these detrimental mutations.
4.2 Future Directions
UDP-glucose dehydrogenase
Our studies of UDP-glucose dehydrogenase highlight several areas
where further study is merited. First of all, the in vitro stability assay for
both the clinical and engineered dimer mutants indicate that the dimeric
mutants exhibit reduced activity over time at 37°C compared to wild-type.
While this suggests that protein stability may be responsible for the clinical
phenotype, confirmation of in vivo protein stability for wild-type and each
dimeric mutant would strengthen this assertion. By using a protein synthesis
inhibitor such as cyclohexamide, the degradation rate of each transiently
transfected UGDH protein can measured. After transfection and expression of
the protein, cyclohexamide is added to prevent continuous protein synthesis.
The depletion of each UGDH protein can then be measured at various time
points by Western blot to establish an in vivo protein half-life for each
mutant and wild-type UGDH.
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Additionally, our measurements of UDP-glucuronate in HEK 293 cells
transiently transfected with mutant and wild-type UGDH did not show any
significant differences in UDP-glucuronate levels, even between the
catalytically inactive mutant UGDH D280N and wild-type (Figure 4.1). In fact,
UGDH D280N had 1.78 times the amount of UDP-glucuronate as wild-type, a
counter-intuitive, if not significant result. While this is disappointing, the
comparably low levels of UDP-glucuronate detected indicate that this
metabolite is rapidly funneled to its many cellular fates and/or tightly
regulated by regulation of UGDH activity.

Figure 4.1. Levels of UDP-glucuronate in HEK 293 cells. HEK 293 cells were transiently
transfected with each construct. UDP-glucuronate levels were measured by HPLC and
normalized to total protein levels. Wild-type level is set equal to one for ease of comparison.
Error bars represent the SEM of three replicates. Control and GFP values have been omitted.
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However, one unexpected and intriguing result from the HPLC data is
the presence of higher amounts of uridine monophosphate (UMP) in the
dimeric mutant transfected cells compared to the wild-type transfected cells.
The levels of UMP were 2 to 5 times higher in the mutants compared to wildtype (Figure 4.2).

Figure 4.2. Levels of uridine monophosphate in HEK 293 cells. HEK 293 cells were
transiently transfected with each construct. Uridine monophosphate levels were measured by
HPLC and normalized to total protein levels. Wild-type level is set equal to one for ease of
comparison. Error bars represent the SEM of three replicates. Control and GFP values have
been omitted.

The two main sources of cellular UMP are de novo biosynthesis
triggered by low levels of UTP and generation in the ER and Golgi lumen from
UDP cleaved from UDP sugars by glycosylation reactions [86, 123-126]. Unlike
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other nucleotide triphosphates, a major part of cellular uridine levels is
comprised of nucleotide-conjugated sugars [125]. These nucleotide sugars are
continually depleted by flux through various metabolic processes. While
regeneration of UTP from UDP and UMP is possible, sometimes UTP is
depleted to a level that triggers UMP biosynthesis [86, 91, 124].
Further studies are necessary to determine whether the increase in
UMP levels observed in the dimeric mutants reflect an impact in in vivo
UGDH activity due to oligomeric state, as well as a proposed mechanism of
any differences. Additionally, the development of new methods to trap UDPglucuronate before it is utilized are essential to understanding in vivo UGDH
activity as well as the relative use of UDP-glucuronate by various cellular
pathways under distinct cellular conditions.
Therefore, further methods of measuring UGDH activity levels in vivo
must be developed. One approach would be to block each UDP-glucuronate
utilizing pathway and measure UDP-glucuronate levels in the cell. This
method would have the advantage of simultaneously informing about the
prevalence of UDP-glucuronate flux through each pathway, at least in the cell
type chosen for the studies. The studies could then be repeated in cell lines
from different tissues and tumors. One example of this type of method that
has been previously employed is the use of 4-methylumbelliferone (4-MU),
which UGTs use a substrate for glucuronidation [88]. The levels of
glucuronidated 4-MU exported to the media can then be measured. The most
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obvious target, especially in HEK293 cells, where UGT abundance and
glycogen formation are expected to be low, is to block glycosyltransfer
reactions in the ER and Golgi lumen. The expected result would be an
accumulation of UDP-glucuronate in the cytosol, and, perhaps, differences in
UDP-glucuronate levels between wild-type and the dimer mutants might then
be detected. Because UDP-glucose is feedback inhibited by UDP-xylose, it
might also be necessary and/or informative to block UDP-glucuronate
decarboxylase or deplete the UDP-xylose levels of the cytosol in order relieve
UGDH inhibition. A recent study in Chinese hamster ovary cells of a mutant
defective in UDP-glucuronate decarboxylase measured an increase of over
100 fold in cellular UDP-glucuronate levels [10]. Therefore, blocking one or
more UDP-glucuronate pathways, either alone or in combination, will allow
us to more accurately measure normal and aberrant in vivo UGDH function.
Another promising and related area of inquiry would be to further
identify and characterize natural and synthetic inhibitors of UGDH function,
both in vitro and in vivo. The recent screen of a large chemical library
conducted for our lab identified a number of inhibitors and activators of
UGDH. Interestingly, quercetin and several related molecules were among the
inhibitors identified. These inhibitors provide a good starting point for in
vitro characterizations using our established kinetic assay. Once an
informative in vivo assay is developed, the most promising inhibitors could be
studied in different tissue types for their effect on UGDH function. Thus,
there are many productive areas to expand and improve our studies of both
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the impacts of oligomeric structure on UGDH function and the further
examination of UGDH function and regulation in vivo.
Glutamate Cysteine Ligase
Continued examination of the structure and function of glutamate
cysteine ligase is essential to understanding the complex active site and
catalytic mechanism of this important redox enzyme. In order to do this, two
continuing projects are underway: 1. Crystallizing the human holoenzyme
and obtaining the structure through x-ray diffraction and 2. Continuing to
examine the enzyme active site through site-directed mutagenesis and kinetic
studies.
Significant progress was made in crystallizing the human
holoenzyme by Katja Biterova, a former member of the lab. She was able to
identify conditions and obtain large protein crystals. However, diffraction of
these crystals was poor and problems were observed in the cryoprotection
process. Thus, further efforts are needed to overcome these limitations and
produce crystals that freeze and diffract well.
For the second objective, a set of key catalytic residues has been
identified in the GCL active site based on examination of the human
homology model and reports in the literature [43, 127]. The following
mutants were cloned, expressed, and purified E96Q, K412A, R185L, R426L,
and W406F.
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Figure 4.3. Catalytic Residues in GCLC. Key residues in the active site of GCLC are shown
in magenta. Magnesium atoms are shown in purple. Panel A. Aspartate 427 and glutamate 96
are shown in the magnesium-coordinating region of the active site, while lysine 412 is
depicted hydrogen bonding with ADP. Mutation of each of these residues resulted in a
catalytically inactive enzyme, in both the GCLC and holoenzyme forms. Panel B. Arginine
185 and tryptophan 406 are shown near the proposed cysteine-binding site. Mutation of
arginine 185 dramatically increases the amount of cysteine required for activity. Mutation of
either residue negatively impacts enzyme catalysis.
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An initial kinetic characterization demonstrated that all of the mutant
enzymes were catalytically inactive in the catalytic-only form, while R185L
and W406F had limited activity in the holoenzyme form. It is not surprising
that E96, R427 and L412 are catalytically inactive because E96 and R427
likely participate in magnesium coordination, while L412 likely hydrogen
bonds with ATP (Figure 4.3, panel A). Further preliminary characterizations
revealed that R185L activity is enhanced in the presence of 25 mM cysteine
rather than the usual 1 mM saturating concentration used for this assay,
suggesting that R185 may be critical for cysteine coordination in the enzyme
active site. Neither mutant appeared to have a significantly altered
requirement for glutamate or ATP.
Determination of the apparent kinetic constants of these GCL
mutants was planned to coincide with the adaptation of the standard kinetic
assay to a high-throughput 96-well plate format. Initial tests of this format
with wild-type enzyme showed that similar kinetic constants could be
obtained using this format compared to the traditional format. An initial test
involving the R185L and W406F mutants demonstrated that the W406F
holoenzyme had approximately ¾ the activity of wild-type, while the R185L
holoenzyme had only ½ the activity of the holoenzyme. Interestingly, the
apparent Km for glutamate of both mutants was almost identical to that of
wild-type.
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After determination of the apparent kinetic constants for these two
catalytic site mutants, other important residues will be identified for similar
studies. For example, the competitive feedback inhibition of glutathione may
be examined by mutating residues that might interact with the glycine
residue of glutathione that is not present in the product of GCL,

-

glutamylcysteine. Thus, while our studies of the GCL clinical mutants yielded
critical insights into catalytic function, further structural studies will
improve our understanding of this essential redox enzyme.
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